WO1998024439A1 - Use of nk-1 receptor antagonists for treating severe anxiety disorders - Google Patents

Use of nk-1 receptor antagonists for treating severe anxiety disorders Download PDF

Info

Publication number
WO1998024439A1
WO1998024439A1 PCT/EP1997/006683 EP9706683W WO9824439A1 WO 1998024439 A1 WO1998024439 A1 WO 1998024439A1 EP 9706683 W EP9706683 W EP 9706683W WO 9824439 A1 WO9824439 A1 WO 9824439A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
treatment
methyl
trifluoromethyl
bis
Prior art date
Application number
PCT/EP1997/006683
Other languages
French (fr)
Inventor
Raymond Baker
Neil Roy Curtis
Jason Matthew Elliott
Timothy Harrison
Gregory John Hollingworth
Philip Stephen Jackson
Janusz Jozef Kulagowski
Nadia Melanie Rupniak
Eileen Mary Seward
Christopher John Swain
Brian John Williams
Original Assignee
Merck Sharp & Dohme Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9625051A external-priority patent/GB9625051D0/en
Priority claimed from GB9701459A external-priority patent/GB9701459D0/en
Priority claimed from GB9713715A external-priority patent/GB9713715D0/en
Priority claimed from GBGB9716471.9A external-priority patent/GB9716471D0/en
Priority claimed from GBGB9721220.3A external-priority patent/GB9721220D0/en
Application filed by Merck Sharp & Dohme Limited filed Critical Merck Sharp & Dohme Limited
Priority to EP97953721A priority Critical patent/EP0942734A1/en
Priority to JP52517098A priority patent/JP2001504848A/en
Priority to AU57527/98A priority patent/AU729708B2/en
Priority to CA002273785A priority patent/CA2273785A1/en
Publication of WO1998024439A1 publication Critical patent/WO1998024439A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Definitions

  • This invention relates to the treatment or prevention of certain anxiety disorders by the administration of a specific class of NK-1 receptor antagonists.
  • Anxiety is an emotional condition characterised by feelings such as apprehension and fear accompanied by physical symptoms such as tachycardia, increased respiration, sweating and tremor. It is a normal emotion but when it is severe and disabling it becomes pathological.
  • Anxiety disorders are generally treated using benzodiazepine sedative-antianxiety agents. Potent benzodiazepines should not be prescribed for more than 3 or 4 weeks, however, due to the risks associated with drug dependency.
  • Tricyclic antidepressants such as amitriptyhne which have both anxiolytic and antidepressant actions may also be used.
  • 5-HTIA receptor agonists and antagonists may also have useful anxiolytic and other psychotropic activity (see R. J.
  • SSRIs serotonin reuptake inhibitors
  • benzodiazepines are also associated with a number of side-effects including increased hostility and irritability, vivid or disturbing dreams, weight gain, skin rash, nausea, headache, impairment of sexual function, vertigo, and lightheadedness. Difficulties may also arise with the use of tricyclic antidepressants, in particular, due to their anticholinergic side-effects which are particularly troublesome in patients with prostatic enlargement or glaucoma.
  • Other side-effects of tricyclic antidepressants include dry mouth, tachycardia, difficulty in visual accomodation, constipation, urinary retention, sexual dysfunction, cognitive impairment, postural hypotension, and weight gam.
  • SSRIs are not without their own side-effects, including nausea, diarrhoea, dry mouth, reduced appetite, dyspepsia, vomiting, headache, nervousness, insomnia, anxiety, tremour, dizziness, fatigue, decreased libido, pharyngitis, dyspnoea, skin rash and sexual dysfunction.
  • Neurokinin 1 (NK-1; substance P) receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinins, and in particular substance P. Examples of conditions in which substance P has been implicated include disorders of the central nervous system such as anxiety, depression and psychosis (see, for instance, International (PCT) patent specification Nos. WO 95/16679, WO 95/18124 and WO 95/23798).
  • European Patent Specification No. 0 286 928 describes inhibitors of the enzyme prolyl-endopeptidase, which enzyme degrades neuropeptides such as substance P, the enzyme inhibitors having an antipsychotic, anxiolytic and antidepressant action.
  • substance P the enzyme inhibitors having an antipsychotic, anxiolytic and antidepressant action.
  • degrading substance P or reducing the action of substance P in some other way might be expected to be detrimental to the treatment of anxiety.
  • the present invention provides the use of a CNS penetrant NK-1 receptor antagonist in an oral, once-a-day medicament for the treatment of severe anxiety disorder.
  • the compounds of this class advantageously exhibit a rapid onset of action and a reduced side-effect profile when compared against conventional anxiolytic agents.
  • the present invention provides a means for the identification of NK-1 receptor antagonists which would be effective in an oral once-a-day medicament for the treatment of severe anxiety disorders.
  • the aforementioned patent specifications which describe NK-1 receptor antagonists provide no reliable method for the identification of such compounds.
  • the exceptional pharmacology of the class of NK-1 receptor antagonists of use in the present invention enables the treatment of severe anxiety disorders, without the need for concomitant therapy using benzodiazepines or tricyclic antidepressants or, in particular, without the need for concomitant use of a serotonin agonist or antagonist or an SSRI. Furthermore, the exceptional pharmacology of the class of NK-1 receptor antagonists of use in the present invention results in a rapid onset of action.
  • the present invention accordingly provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist (as hereinafter defined) for the manufacture of a medicament adapted for oral administration for the treatment or prevention of severe anxiety disorders without concomitant therapy with other anti-anxiety agents.
  • the present invention also provides a method for the treatment or prevention of severe anxiety disorders without concomitant therapy with other anti-anxiety agents, which method comprises the oral administration to a patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist (as hereinafter defined).
  • an oral pharmaceutical composition for the treatment of severe anxiety disorders which comprises essentially an orally active, long acting, CNS- penetrant NK-1 receptor antagonist (as hereinafter defined), together with a pharmaceutically acceptable carrier or excipient.
  • the present invention accordingly provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to benzodiazepines or for whom benzodiazepines are contraindicated.
  • the present invention also provides a method for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to benzodiazepines or for whom benzodiazepines are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS- penetrant NK-1 receptor antagonist.
  • a patient population in whom severe anxiety disorders are inadequately treated with tricyclic antidepressants.
  • some patients may be adversely affected by the side-effects of tricyclic antidepressants.
  • the present invention accordingly provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to tricyclic antidepressants or for whom tricyclic antidepressants are contraindicated.
  • the present invention also provides a method for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to tricyclic antidepressants or for whom tricyclic antidepressants are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS- penetrant NK-1 receptor antagonist.
  • the present invention accordingly provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to SSRIs or serotonin agonists or antagonists or for whom SSRIs or serotonin agonists or antagonists are contraindicated.
  • the present invention also provides a method for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in the patient who is non-responsive to SSRIs or serotonin agonists or antagonists or for whom SSRIs or serotonin agonists or antagonists are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.
  • non-responsive in relation to severe anxiety disorders means patients who have not had a reasonable clinical response (e.g. a 50% reduction in Hamilton Anxiety Scale (HAM-A) from a patient's baseline score after treatment with one or more clinical courses of conventional anxiolytics).
  • HAM-A Hamilton Anxiety Scale
  • panic anxiety disorders includes panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, social phobias and obsessive-compulsive disorder.
  • Panic disorder is defined as the presence of recurrent panic attacks followed by at least one month of persistent concern about having another panic attack.
  • a “panic attack” is a discrete period in which there is a sudden onset of intense apprehension, fearfulness or terror.
  • the individual may experience a variety of symptoms including palpitations, sweating, trembling, shortness of breath, chest pain, nausea and dizziness. Panic disorder may occur with or without agoraphobia.
  • Phobias includes agoraphobia, specific phobias and social phobias.
  • Agoraphobia is characterised by an anxiety about being in places or situations from which escape might be difficult or embarrassing or in which help may not be available in the event of a panic attack. Agoraphobia may occur without history of a panic attack.
  • a “specific phobia” is characterised by clinically significant anxiety provoked by exposure to a specific feared object or situation.
  • Specific phobias include the following subtypes: animal type, cued by animals or insects; natural environment type, cued by objects in the natural environment, for example storms, heights or water; blood-injection-injury type, cued by the sight of blood or an injury or by seeing or receiving an injection or other invasive medical procedure; situational type, cued by a specific situation such as public transportation, tunnels, bridges, elevators, flying, driving or enclosed spaces; and other type where fear is cued by other stimuli.
  • Specific phobias may also be referred to as simple phobias.
  • a "social phobia” is characterised by clinically significant anxiety provoked by exposure to certain types of social or performance circumstances. Social phobia may also be referred to as social anxiety disorder.
  • Obsessive-compulsive disorder is characterised by recurrent obsessions or compulsions that are severe enough to be time consuming (i.e. they take at least one hour a day) or cause marked distress or significant impairment. At some point during the course of the disorder, the patient should recognise that the obsessions or compulsions are excessive or unreasonable.
  • anxiety disorders encompassed within the term “severe anxiety disorders” include anxiety disorders induced by alcohol, amphetamines, caffeine, cannabis, cocaine, hallucinogens, inhalants, phencyclidine, sedatives, hypnotics, anxiolytics and other substances, and adjustment disorders with anxiety.
  • treatment refers both to the treatment and to the prevention or prophylactic therapy of the aforementioned conditions.
  • Preferred NK-1 receptor antagonists for use in the present invention are selected from the classes of compounds described in
  • NK-1 receptor antagonists of use in the present invention include:
  • Suitable pharmaceutically acceptable salts of the NK-1 receptor antagonists of use in the present invention include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid.
  • Salts of amine groups may also comprise the quaternary ammonium salts in which the amino nitrogen atom carries an alkyl, alkenyl, alkynyl or aralkyl group.
  • the present invention also contemplates salts thereof, preferably non-toxic pharmaceutically acceptable salts thereof, such as the sodium, potassium and calcium salts thereof.
  • compositions containing an NK-1 receptor antagonist of use according to the present invention are in unit dosage forms such as tablets, pills, capsules, wafers and the like.
  • the NK-1 receptor antagonists of use according to the present invention may be presented as granules or powders for extemporaneous formulation as volume defined solutions or suspensions.
  • the NK-1 receptor antagonists of use according to the present invention may be presented in ready-prepared volume defined solutions or suspensions.
  • Preferred forms are tablets and capsules.
  • the principal active ingredient is mixed with a pharmaceutical carrier, e.g.
  • a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof.
  • preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
  • the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
  • liquid forms in which the novel compositions of the present invention may be incorporated for administration orally include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, peanut oil or soybean oil, as well as elixirs and similar pharmaceutical vehicles.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymeth lcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
  • compositions of the present invention may also be administered via the buccal cavity using conventional technology, for example, absorption wafers.
  • Compositions in the form of tablets, pills, capsules or wafers for oral administration are particularly preferred.
  • a minimum dosage level for the NK-1 receptor antagonist is about lmg per day, preferably about 5mg per day and especially about lOmg per day.
  • a maximum dosage level for the NK-1 receptor antagonist is about 1500mg per day, preferably about lOOOmg per day and especially about 500mg per day. The compounds are administered once a day.
  • the amount of the NK-1 receptor antagonist required for use in the treatment or prevention of severe anxiety disorders will vary not only with the particular compounds or compositions selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the patient's physician or pharmacist.
  • THF (0.91M, 3ml) (Louw et. al., Tetrahedron, 48, 6087-6104, 1992, prepared from 2.74mmol of 3-chloro-2-(phenoxymethyl)-l-propene) was slowly added to a solution of (2.S)-l-t.ert.-butoxycarbonyl-2-phenylpiperidin- 3-one (Preparation 1) in THF (3ml). The mixture was stirred at room temperature for 1 hours, then saturated aqueous ammonium chloride (20ml) was added and the mixture was extracted with ethyl acetate (20ml). The organic phase was washed with brine, dried (MgS0 ) and the solvent was evaporated under reduced pressure .
  • the mixture was degassed with bubbling nitrogen and heated under reflux for 16 hours.
  • the mixture was cooled and the solvent was evaporated under reduced pressure.
  • the residue was partitioned between ethyl acetate and 2M sodium hydroxide.
  • the organic phase was washed with saturated brine, dried (MgSO ) and purified by chromatography on a column containing silica gel (eluting with hexane containing increasing proportions of ethyl acetate between 0% to 5%).
  • O-Trimethylsilylpropargyl alcohol 24.51ml, 20.47g, 160ml was added slowly to a cooled (-10°C) solution of ethylmagnesium bromide (IM in tetrahydrofuran, 160ml, 160mmol).
  • IM ethylmagnesium bromide
  • the mixture was stirred at 0°C for 20 minutes, then at room temperature for 2 hours.
  • the mixture was cooled to -10°C and a solution of (2S)-l-ter£-butoxycarbonyl-2- phenylpiperidin-3-one (Preparation 1; 42.3g) in tetrahydrofuran (200ml) was added dropwise over 30 minutes. (Internal temperature below - ⁇ °C).
  • the aqueous layer was extracted with ethyl acetate (2x300ml) and the combined organic fractions were washed with 5 water (300ml) and brine (300ml), dried (MgSO 4 ) and the solvent was evaporated under reduced pressure to give the crude title compound as an orange oil (45g).
  • the crude material was purified by flash column chromatography on silica gel, eluting with hexane/ethyl acetate (90:10 increasing to 2 ⁇ :7 ⁇ ) to give the title compound as an amber oil (32.2g).
  • Benzyl bromide (66.17ml, 9 ⁇ .3 ⁇ g, O. ⁇ 6mol) was added to a mixture of 4-(trifluoromethoxy)phenol (90.26g, O. ⁇ lmol) and potassium carbonate (140.97g, 1.2mol) in dimethylformamide (160ml) and the mixture was
  • a further compound and diastereomers thereof of use in the present invention may be prepared according to the following method:
  • Iron(lll)nitrate nonahydrate (1.97 g, 4.87 mmol) was added to a solution of 4-(trifluoromethoxy)phenol (2 g, 11.24 mmol) in ethanol (20 mL) and the mixture was heated under reflux overnight. The mixture was
  • NK-1 receptor antagonists of use in the present invention are compounds which are potent NK-1 receptor antagonists, i.e. compounds with an NK-1 receptor affinity (IC 50 ) of less than lOnM, favourably less than 2nM and preferably less than InM.
  • IC 50 NK-1 receptor affinity
  • NK-1 receptor antagonists of use in the present invention is identified using a combination of the following assays:
  • ASSAY 1 NK-1 Receptor binding
  • NK-1 receptor binding assays are performed in intact Chinese hamster ovary (CHO) cells expressing the human NK-1 receptor using a modification of the assay conditions described by Cascieri et al, J. Pharmacol. Exp. Ther., 1992, 42, 468. Typically, the receptor is expressed at a level of 3xl0 5 receptors per cell. Cells are grown in monolayer culture, detached from the plate with enzyme-free dissociation solution (Speciality Media Inc.), and washed prior to use in the assay.
  • 5I-Tyr 8 - substance P (O.lnM, 2000Ci/mmol; New England Nuclear) is incubated in the presence or absence of test compounds (dissolved in 5 ⁇ l dimethylsulphoxide, DMSO) with ⁇ xlO 4 CHO cells.
  • Ligand binding is performed in 0.25ml of 50mM Tris-HCl, pH7. ⁇ , containing 5mM MnC- 2 , l ⁇ OmM NaCl, 0.02% bovine serum albumin (Sigma), 50 ⁇ g/ml chymostatin (Peninsula), O.lnM phenylmethylsulphonyl fluoride, 2 ⁇ g/ml pepstatin, 2 ⁇ g/ml leupeptin and 2.8 ⁇ g/ml furoyl saccharine.
  • the incubation proceeds at room temperature until equilibrium is achieved (>40 minutes) and the receptor-ligand complex is harvested by filtration over GF/C filters pre- soaked in 0.1% polyethylenimine using a Tomtek 96-well harvester. Nonspecific binding is determined using excess substance P (l ⁇ M) and represents ⁇ 10% of total binding.
  • Gerbil Foot-Tapping CNS-penetrant NK-1 receptor antagonists for use in the present invention can be identified by their ability to inhibit foot tapping in gerbils induced by anxiogenic agents (such as pentagastrin) or central infusion of NK-1 receptor agonists such as GR73632, or caused by aversive stimulation such as foot shock or single housing, based on the method of Rupniak & Williams, Eur. J. Pharmacol, 1994, 265, 179.
  • test compounds Male or female Mongolian gerbils (35-70g) are anaesthetised by inhalation of an isoflurane/oxygen mixture to permit exposure of the jugular vein in order to permit administration of test compounds or vehicle in an injection volume of ⁇ ml/kg i.v.
  • test compounds may be administered orally or by subcutaneous or intraperitoneal routes. A skin incision is then made in the midline of the scalp to expose the skull.
  • An anxiogenic agent e.g. pentagastrin
  • a selective NK-1 receptor agonist e.g.
  • GR73632 (d Ala[L-Pro 9 ,Me-Leu 10 ]-substance P-(7-ll)) is infused directly into the cerebral ventricles (e.g. 3pmol in 5 ⁇ l i.c.v., depending on test substance) by vertical insertion of a cuffed 27 gauge needle to a depth of 4.5mm below bregma. The scalp incision is closed and the animal allowed to recover from anaesthesia in a clear perspex observation box (25cm x 20cm x 20cm). The duration and/or intensity of hind foot tapping is then recorded continuously for approximately 5 minutes. Alternatively, the ability of test compounds to inhibit foot tapping evoked by aversive stimulation, such as foot shock or single housing, may be studied using a similar method of quantification.
  • ferrets Individually housed male ferrets (1.0 -2.5 kg) are dosed orally by gavage with test compound. Ten minutes later they are fed with approximately lOOg of tinned cat food. At 60 minutes following oral dosing, cisplatin (lOmg/kg) is given i.v. via a jugular vein catheter inserted under a brief period of halothane anaesthesia. The catheter is then removed, the jugular vein ligated and the skin incision closed. The ferrets recover rapidly from the anaesthetic and are mobile within 10-20 minutes. The animals are observed continuously during recovery from the - DO -
  • ASSAY 4 Separation-Induced Vocalisation
  • mice Male and female guinea-pigs pups are housed in family groups with their mothers and littermates throughout the study. Experiments are commenced after weaning when the pups are 2 weeks old. Before entering an experiment, the pups are screened to ensure that a vigorous vocalisation response is reproducibly elicited following maternal separation. The pups are placed individually in an observation cage (5 ⁇ cm x 39cm x 19cm) in a room physically isolated from the home cage for 15 minutes and the duration of vocalisation during this baseline period is recorded. Only animals which vocalise for longer than 5 minutes are employed for drug challenge studies (approximately 50% of available pups may fail to reach this criterion). On test days each pup receives an oral dose or an s.c. or i.p.
  • test compound or vehicle injection of test compound or vehicle and is then immediately returned to the home cage with its mother and siblings for 30 to 60 minutes (or for up to 4 hours following an oral dose, dependent upon the oral pharmacokinetics of the test compound) before social isolation for 15 minutes as described above.
  • the duration of vocalisation on drug treatment days is expressed as a percentage of the pre-treatment baseline value for each animal. The same subjects are retested once weekly for up to 6 weeks. Between 6 and 8 animals receive each test compound at each dose tested.
  • CNS-penetrant refers to NK-1 receptor antagonists which are able to inhibit NK-1 receptor antagonist-induced foot-tapping in the gerbil as hereinafter defined. Essentially, hind foot-tapping in the gerbil induced by infusion of the NK-1 receptor agonist, GR73632 (d Ala[L-Pro 9 ,Me-Leu 10 ] -substance P- - ⁇ b -
  • the NK-1 receptor antagonist is administered orally, 1 hour prior to GR73632 challenge, wherein the foot- tapping over a period of five minutes following recovery from anaesthesia is inhibited with an IDso ⁇ 30mg/kg, and preferably with an IDso ⁇ lOmg/kg.
  • CNS-penetrant NK-1 receptor antagonists of use in the present ivnention are also effective in the attenuation of separation-induced vocalisations by guinea-pig pups as hereinafter defined.
  • a vocalisation response in guinea-pig pups is induced by isolation from their mothers and littermates, which response is attenuated when a CNS-penetrant NK-1 receptor antagonist is administered subcutaneously 30 minutes prior to isolation, wherein vocalisations during the first 15 minutes of isolation are attenuated with an ID5 0 ⁇ 20mg/kg, preferably with an IDso ⁇ lOmg/kg, and especially with an IDso ⁇ mg/kg.
  • the NK-1 receptor antagonist is administered orally, 4 hours prior to isolation, wherein vocalisations during the first l ⁇ minutes of isolation are attenuated with an ID 5 o ⁇ 20mg/kg, preferably with an IDso ⁇ lOmg/kg, and especially with an IDso ⁇ mg/kg.
  • a suitable selection cascade for NKi antagonists of use according to the present invention is as follows:
  • Particularly preferred compounds of use in the present invention are identified using steps (i) to (iv) followed by step (v): (v) Determine activity of compounds in assays sensitive to conventional antipsychotic drugs (inhibition of distress vocalisations in guinea-pig pups (Assay 4)). Select compounds with ID50 ⁇ 20mg/kg, and preferably ID50 ⁇ lOmg/kg.
  • Yet further preferred compounds of use in the present invention may be selected from those compounds which satisfy the NK-1 receptor binding criteria of step (i) which, in addition, have ⁇ 5-fold shift in affinity when incubated in the presence of human serum albumin (HSA) to show non-specific protein binding.
  • HSA human serum albumin
  • a NK-1 receptor antagonist of use in the present invention is the compound 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)- ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-lH,4H-l,2,4-triazolo)methyl)- morpholine, the preparation of which is described in International Patent Specification No. WO 95/16679. In the aforementioned assays, this compound has the following activity:
  • the active ingredient, cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste.
  • the resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate.
  • the resulting granulation is then compressed into tablets containing 50mg, lOOmg and 300mg of the NK-1 receptor antagonist per tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist in a medicament adapted for oral administration for the treatment or prevention of severe anxiety disorders without concomitant therapy with other anti-anxiety agents, methods of treatment using such an NK-1 receptor antagonist and pharmaceutical compositions comprising it.

Description

USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEVERE ANXIETY DISORDERS
This invention relates to the treatment or prevention of certain anxiety disorders by the administration of a specific class of NK-1 receptor antagonists.
Anxiety is an emotional condition characterised by feelings such as apprehension and fear accompanied by physical symptoms such as tachycardia, increased respiration, sweating and tremor. It is a normal emotion but when it is severe and disabling it becomes pathological. Anxiety disorders are generally treated using benzodiazepine sedative-antianxiety agents. Potent benzodiazepines should not be prescribed for more than 3 or 4 weeks, however, due to the risks associated with drug dependency. Tricyclic antidepressants (TCAs) such as amitriptyhne which have both anxiolytic and antidepressant actions may also be used. 5-HTIA receptor agonists and antagonists may also have useful anxiolytic and other psychotropic activity (see R. J. Baldessarini in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, Chapter 18, McGraw-Hill, 1996 for a review). Selective serotonin reuptake inhibitors (SSRIs) are also widely prescribed for the treatment of anxiety.
Apart from the risks of drug dependency, benzodiazepines are also associated with a number of side-effects including increased hostility and irritability, vivid or disturbing dreams, weight gain, skin rash, nausea, headache, impairment of sexual function, vertigo, and lightheadedness. Difficulties may also arise with the use of tricyclic antidepressants, in particular, due to their anticholinergic side-effects which are particularly troublesome in patients with prostatic enlargement or glaucoma. Other side-effects of tricyclic antidepressants include dry mouth, tachycardia, difficulty in visual accomodation, constipation, urinary retention, sexual dysfunction, cognitive impairment, postural hypotension, and weight gam. SSRIs are not without their own side-effects, including nausea, diarrhoea, dry mouth, reduced appetite, dyspepsia, vomiting, headache, nervousness, insomnia, anxiety, tremour, dizziness, fatigue, decreased libido, pharyngitis, dyspnoea, skin rash and sexual dysfunction. Neurokinin 1 (NK-1; substance P) receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinins, and in particular substance P. Examples of conditions in which substance P has been implicated include disorders of the central nervous system such as anxiety, depression and psychosis (see, for instance, International (PCT) patent specification Nos. WO 95/16679, WO 95/18124 and WO 95/23798).
On the other hand, European Patent Specification No. 0 286 928 describes inhibitors of the enzyme prolyl-endopeptidase, which enzyme degrades neuropeptides such as substance P, the enzyme inhibitors having an antipsychotic, anxiolytic and antidepressant action. Thus, degrading substance P or reducing the action of substance P in some other way (e.g. antagonism at its preferred NK-1 receptor) might be expected to be detrimental to the treatment of anxiety.
More recently, International (PCT) patent specification No. WO 96/24353 (published 15th August 1996) suggests that a more efficacious and safe treatment of psychiatric disorders would be achieved using a combination of a tachykinin antagonist and a serotonin agonist or selective serotonin reuptake inhibitor (SSRI). However, such a regimen would not be free of side-effects due to the serotonin agonist or SSRI. NK-1 receptor antagonists are described in published European
Patent Specification Nos. 0 360 390, 0 394 989, 0 429 366, 0 443 132, 0 482 539, 0 512 901, 0 512 902, 0 514 273, 0 514 275, 0 517 589, 0 520 555, 0 522 808, 0 528 495, 0 532 456, 0 533 280, 0 536 817, 0 545 478, 0 577 394, 0 590 152, 0 599 538, 0 610 793, 0 634 402, 0 686 629, 0 693 489, 0 694 535, 0 699 655, 0 699 674, 0 707 006, 0 708 101, 0 714 891, 0 723 959, 0 733 632 and 0 776 893; and in International Patent Specification Nos. 90/05525, 90/05729, 91/09844, 91/18899, 92/01688, 92/06079, 92/12151, 92/15585, 92/17449, 92/20661, 92/20676, 92/21677, 93/00330, 93/00331, 93/01159, 93/01165, 93/01169, 93/01170, 93/06099, 93/09116, 93/10073, 93/14113, 93/18023, 93/19064, 93/21155, 9321181, 93/23380, 93/24465, 94/01402, 94/02461, 94/03429, 94/03445, 94/04494, 94/04496, 94/05625, 94/07843, 94/10165, 94/10167, 94/10168, 94/10170, 94/11368, 94/13639, 94/13663, 94/14767, 94/15903, 94/19320, 94/19323, 94/20500, 94/26735, 94/26740, 94/29309, 95/02595, 95/04040, 95/04042, 95/06645, 95/07886, 95/07908, 95/08549, 95/11880, 95/14017, 95/15311, 95/16679, 95/17382, 95/18124, 95/18129, 95/19344, 95/20575, 95/21819, 96/22525, 95/23798, 95/26338, 95/28418, 95/30674, 95/30687, 96/05193, 96/05203, 96/06094, 96/07649, 96/10562, 96/16939, 96/18643, 96/20197, 96/21661, 96/29304, 96/29317, 96/29326, 96/29328, 96/31214, 96/32385, 96/37489, 97/01553, 97/01554, 97/03066, 97/08144, 97/14671, 97/17362, 97/18206, 97/19084, 97/19942 and 97/21702; and in British Patent Specification Nos. 2 266 529, 2 268 931, 2 269 170, 2 269 590, 2 271 774, 2 292 144, 2 293 168, 2 293 169, and 2 302 689.
In view of the short-comings of existing anti-anxiety therapy, there is a need for new, safe and effective treatment for severe anxiety disorders. The present invention provides the use of a CNS penetrant NK-1 receptor antagonist in an oral, once-a-day medicament for the treatment of severe anxiety disorder. The compounds of this class advantageously exhibit a rapid onset of action and a reduced side-effect profile when compared against conventional anxiolytic agents. In particular, the present invention provides a means for the identification of NK-1 receptor antagonists which would be effective in an oral once-a-day medicament for the treatment of severe anxiety disorders. The aforementioned patent specifications which describe NK-1 receptor antagonists provide no reliable method for the identification of such compounds. The exceptional pharmacology of the class of NK-1 receptor antagonists of use in the present invention enables the treatment of severe anxiety disorders, without the need for concomitant therapy using benzodiazepines or tricyclic antidepressants or, in particular, without the need for concomitant use of a serotonin agonist or antagonist or an SSRI. Furthermore, the exceptional pharmacology of the class of NK-1 receptor antagonists of use in the present invention results in a rapid onset of action.
The present invention accordingly provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist (as hereinafter defined) for the manufacture of a medicament adapted for oral administration for the treatment or prevention of severe anxiety disorders without concomitant therapy with other anti-anxiety agents.
The present invention also provides a method for the treatment or prevention of severe anxiety disorders without concomitant therapy with other anti-anxiety agents, which method comprises the oral administration to a patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist (as hereinafter defined). In a further aspect of the present invention, there is provided an oral pharmaceutical composition for the treatment of severe anxiety disorders which comprises essentially an orally active, long acting, CNS- penetrant NK-1 receptor antagonist (as hereinafter defined), together with a pharmaceutically acceptable carrier or excipient. There exists a patient population in whom severe anxiety disorders are inadequately treated with benzodiazepines. Furthermore, some patients may be adversely affected by the side-effects of benzodiazepines.
The present invention accordingly provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to benzodiazepines or for whom benzodiazepines are contraindicated.
The present invention also provides a method for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to benzodiazepines or for whom benzodiazepines are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS- penetrant NK-1 receptor antagonist. Furthermore, there exists a patient population in whom severe anxiety disorders are inadequately treated with tricyclic antidepressants. Furthermore, some patients may be adversely affected by the side-effects of tricyclic antidepressants.
The present invention accordingly provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to tricyclic antidepressants or for whom tricyclic antidepressants are contraindicated.
The present invention also provides a method for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to tricyclic antidepressants or for whom tricyclic antidepressants are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS- penetrant NK-1 receptor antagonist.
Furthermore, there exists a patient population in whom severe anxiety disorders are inadequately treated with SSRIs or serotonin agonists or antagonists. Furthermore, some patients may be adversely affected by the side-effects of SSRIs or serotonin agonists or antagonists. The present invention accordingly provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to SSRIs or serotonin agonists or antagonists or for whom SSRIs or serotonin agonists or antagonists are contraindicated.
The present invention also provides a method for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in the patient who is non-responsive to SSRIs or serotonin agonists or antagonists or for whom SSRIs or serotonin agonists or antagonists are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.
As used herein, the term "non-responsive" in relation to severe anxiety disorders means patients who have not had a reasonable clinical response (e.g. a 50% reduction in Hamilton Anxiety Scale (HAM-A) from a patient's baseline score after treatment with one or more clinical courses of conventional anxiolytics).
As used herein, the term "severe anxiety disorders" includes panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, social phobias and obsessive-compulsive disorder. "Panic disorder" is defined as the presence of recurrent panic attacks followed by at least one month of persistent concern about having another panic attack. A "panic attack" is a discrete period in which there is a sudden onset of intense apprehension, fearfulness or terror. During a panic attack, the individual may experience a variety of symptoms including palpitations, sweating, trembling, shortness of breath, chest pain, nausea and dizziness. Panic disorder may occur with or without agoraphobia.
"Phobias" includes agoraphobia, specific phobias and social phobias. "Agoraphobia" is characterised by an anxiety about being in places or situations from which escape might be difficult or embarrassing or in which help may not be available in the event of a panic attack. Agoraphobia may occur without history of a panic attack. A "specific phobia" is characterised by clinically significant anxiety provoked by exposure to a specific feared object or situation. Specific phobias include the following subtypes: animal type, cued by animals or insects; natural environment type, cued by objects in the natural environment, for example storms, heights or water; blood-injection-injury type, cued by the sight of blood or an injury or by seeing or receiving an injection or other invasive medical procedure; situational type, cued by a specific situation such as public transportation, tunnels, bridges, elevators, flying, driving or enclosed spaces; and other type where fear is cued by other stimuli. Specific phobias may also be referred to as simple phobias. A "social phobia" is characterised by clinically significant anxiety provoked by exposure to certain types of social or performance circumstances. Social phobia may also be referred to as social anxiety disorder.
"Obsessive-compulsive disorder is characterised by recurrent obsessions or compulsions that are severe enough to be time consuming (i.e. they take at least one hour a day) or cause marked distress or significant impairment. At some point during the course of the disorder, the patient should recognise that the obsessions or compulsions are excessive or unreasonable.
Other anxiety disorders encompassed within the term "severe anxiety disorders" include anxiety disorders induced by alcohol, amphetamines, caffeine, cannabis, cocaine, hallucinogens, inhalants, phencyclidine, sedatives, hypnotics, anxiolytics and other substances, and adjustment disorders with anxiety. As used herein, the term "treatment" refers both to the treatment and to the prevention or prophylactic therapy of the aforementioned conditions.
Preferred NK-1 receptor antagonists for use in the present invention are selected from the classes of compounds described in
European Patent Specification No. 0 577 394, and International Patent
Specification Nos. 95/08549, 95/18124, 95/23798 and 96/05181, and
International Patent Application No. PCT/GB97/01630. The preparation of such compounds is fully described in the aforementioned publications. Particularly preferred NK-1 receptor antagonists of use in the present invention include:
2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3(S)-(4-fluorophenyl)-4-(3-(5-oxo- lH,4H-l,2,4-triazolo)methyl)morpholine;
2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(3-(5-oxo-lH,4H- l,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;
2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-4-(3-(5-oxo-lH,4H-l,2,4- triazolo)methyl)-3-(S)-phenyl-morpholine;
2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(3-(5-oxo-lH,4H-l,2,4-triazolo)methyl)morpholine; 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N- dimethylamino)methyl-l,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine;
2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N- dimethylamino)methyl-l,2,3-triazol-4-yl)methyl-3-(S)-(4- fluorop he ny 1) morpholine ; 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(3-(4-monophosphoryl-5-oxo-lH-l,2,4-triazolo)methyl)morpholine;
2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(3-(l-monophosphoryl-5-oxo-lH-l,2,4-triazolo)methyl)morpholine;
2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)- 4-(3-(2-monophosphoryl-5-oxo-lH-l,2,4-triazolo)methyl)morpholine; 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)- 4-(3-(5-oxyphosphoryl-lH-l,2,4-triazolo)methyl)morpholine; 2-(S)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)- 4-(3-(l-monophosphoryl-5-oxo-4H-l,2,4-triazolo)methyl)morpholine; 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-N,N- dimethy laminobut- 2-y n-y 1)- 3- (S) - (4-fluorophenyl)morpholine ; (3S,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-l-oxa- 7-aza-spiro[4.5]decane; (3R,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-l-oxa- 7-aza-spiro[4.5]decane; or a pharmaceutically acceptable salt thereof.
Full descriptions of the preparation of the NK-1 receptor antagonists which may be employed in the present invention may be found in the references cited herein. Suitable pharmaceutically acceptable salts of the NK-1 receptor antagonists of use in the present invention include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid. Salts of amine groups may also comprise the quaternary ammonium salts in which the amino nitrogen atom carries an alkyl, alkenyl, alkynyl or aralkyl group. Where the compound carries an acidic group, for example a carboxylic acid group, the present invention also contemplates salts thereof, preferably non-toxic pharmaceutically acceptable salts thereof, such as the sodium, potassium and calcium salts thereof.
Preferably the compositions containing an NK-1 receptor antagonist of use according to the present invention are in unit dosage forms such as tablets, pills, capsules, wafers and the like. Additionally, the NK-1 receptor antagonists of use according to the present invention may be presented as granules or powders for extemporaneous formulation as volume defined solutions or suspensions. Alternatively, the NK-1 receptor antagonists of use according to the present invention may be presented in ready-prepared volume defined solutions or suspensions. Preferred forms are tablets and capsules. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, peanut oil or soybean oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymeth lcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
Compositions of the present invention may also be administered via the buccal cavity using conventional technology, for example, absorption wafers. Compositions in the form of tablets, pills, capsules or wafers for oral administration are particularly preferred.
A minimum dosage level for the NK-1 receptor antagonist is about lmg per day, preferably about 5mg per day and especially about lOmg per day. A maximum dosage level for the NK-1 receptor antagonist is about 1500mg per day, preferably about lOOOmg per day and especially about 500mg per day. The compounds are administered once a day.
It will be appreciated that the amount of the NK-1 receptor antagonist required for use in the treatment or prevention of severe anxiety disorders will vary not only with the particular compounds or compositions selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the patient's physician or pharmacist.
Two compounds of use in the present invention which are described in International Patent Application No. PCT/GB97/01630 may be prepared according to the following methods:
PREPARATION 1
(25r)-l-^βrt-Butoxycarbonyl-2-phenylpiperidin-3-one Dimethyl sulfoxide (20.80ml, 22.90g, 29.3mmol) in dichloromethane
(75ml) was added dropwise to a cooled (-70°C) solution of oxalyl chloride (13.95ml, 20.30g, 160mmol) in dichloromethane (350ml). The mixture was stirred at -70°C for 15 minutes, then (2S,3S)-l-teri-butoxycarbonyl-3- hydroxy-2-phenylpiperidine (prepared by the method described in European Patent Specification number 0 528 495-A; 36.91g, 133mmol) in dichloromethane (150ml) was added dropwise. The mixture was stirred at -70 °C for 20 minutes, then allowed to warm to -30°C. The mixture was cooled to -50 °C and triethylamine (55.95ml, 40.45g, 400mmol) was added slowly. The mixture was allowed to warm to 0°C and diluted with ice- cooled dichloromethane (250ml). The mixture was washed with ice cold aqueous citric acid solution (5%, 2x300ml) and water (300ml), dried
(MgSO ), and the solvent was evaporated under reduced pressure to give the title compound as a yellow oil (42.3g), which was used immediately without further purification. Η NMR (250MHz, CDC13) δ 7.5-7.3 (5H, m), 5.8 (1H, br s), 4.2 (1H, br s), 3.4 (1H, m), 2.6 (2H, m), 2.0 (2H, m), and 1.54 (9H, s).
PREPARATION 2
(2S,3i?)-l-fer -Butoxycarbonyl-3-hvdroxy-3-(2-methylene-3- p he nox yp r op y 1) - 2 -p he n yip ip e r idine A solution of 3-(chloromagnesio)-2-(phenoxymethyl)-l-propene in
THF (0.91M, 3ml) (Louw et. al., Tetrahedron, 48, 6087-6104, 1992, prepared from 2.74mmol of 3-chloro-2-(phenoxymethyl)-l-propene) was slowly added to a solution of (2.S)-l-t.ert.-butoxycarbonyl-2-phenylpiperidin- 3-one (Preparation 1) in THF (3ml). The mixture was stirred at room temperature for 1 hours, then saturated aqueous ammonium chloride (20ml) was added and the mixture was extracted with ethyl acetate (20ml). The organic phase was washed with brine, dried (MgS0 ) and the solvent was evaporated under reduced pressure . The residue was purified by column chromatography on silica gel, eluting with hexane/ethyl acetate (100:0 increasing to 80:20) to give the title compound. *H NMR (360MHz, CDCI3) δ 7.48 (2H, d, J=6.9 Hz), 7.35-7.2 (6H, m), 6.9-6.88 (3H. m), 5.4 - -
(IH, s), 5.15 (2H, d, =13.7 Hz), 4.61 (2H, s), 4.11 (2H, m), 3.17 (IH, m), 2.66 and 2.59 (2H, AB d, =14.0 Hz), 1.95 (2H, m), 1.79 (2H, m), and 1.36 (9H, s). m/z (ES+) 424 (M+l).
PREPARATION 3
(5i?,6g)-3-Methylene-6-phenyl-l-oxa-7-(tβrt.-butoxycarbonyl)aza- spiro[4.5]decane
To a cooled(-80 °C) solution of (2S,3i?)-l-ter«-butoxycarbonyl-3- hydroxy-3-(2-methylene-3-phenoxypropyl)-2-phenylpiperidine (Preparation 2, 1.53g, 3.62mmol) in THF (20ml) was added n-butyl lithium (2.5M in hexanes, 1.45ml, 3.62mmol) followed by a solution of zinc chloride (0.5M in THF, 7.24ml, 3.62mmol). The solution was allowed to warm to room temperature and tetrakis(triphenylphosphine)palladium (0) (0.23g, 0.2mmol) was added. The mixture was degassed with bubbling nitrogen and heated under reflux for 16 hours. The mixture was cooled and the solvent was evaporated under reduced pressure. The residue was partitioned between ethyl acetate and 2M sodium hydroxide. The organic phase was washed with saturated brine, dried (MgSO ) and purified by chromatography on a column containing silica gel (eluting with hexane containing increasing proportions of ethyl acetate between 0% to 5%).
Evaporation of the fractions gave (6S,5R)-3-methylene-6-phenyl-l-oxa- 7- (tert-butoxycarbonyl)aza-spiro[4.5]decane. Η NMR (360MHz, CDC1 ) δ 7.58 (2H, d, =8.4 Hz), 7.32-7.21 (3H, m), 5.23 (IH, s), 5.06 (IH, m), 4.97 (IH, m), 4.39 (2H, AB d, =13.3 Hz), 3.99 (IH, dd, =13.3, 4.48 Hz), 2. 83 (IH, ABd =15.5 Hz), 2.7 (lH.td =12.5, 3.93 Hz), 2.5 (IH, ABd, =15.4 Hz), 2.15 (2H, td, =12., .4 Hz), 1.69 (2H, m), and 1.46 (9H,s). m/z (ES+) 329 (M+2H-tBuOCO). PREPARATION 4
(5i?,6Sr)-3-Keto-6-phenyl-l-oxa-7-(fert-butoxycarbonyl)aza-spiror4.51decane Through a cooled (-80 °C) solution of (5i?,6S)-3-methylene-6-phenyl- l-oxa-7-(£er£-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 3; 0.665g) in dichloromethane (5ml) and methanol (5ml) was bubbled a mixture of ozone and oxygen for 45 minutes. After the solution had been purged with nitrogen, dimethyl sulphide (0.5ml) was added and then stirred under nitrogen at room temperature for 16 hours. The solvent was removed in vacuo and the residue partitioned between ethyl acetate and water. The organic phase was dried (MgSO ), evaporated and the residue purified by chromatography on a column containing silica gel (eluting with hexane containing increasing proportions of ethyl acetate between 0% to 10%). Evaporation of the fractions gave the title compound. *H NMR (250MHz, CDCla) δ 7.58 (2H, d, =6.2 Hz), 7.37-7.26 (3H, m), 5.3 (IH, s), 4.15 and 4.09 (2H, AB d, =17.4 Hz), 3.97 (IH, m), 2.80 (IH, td, =12.9, 4.0 Hz), 2.74 and 2.48 (2H, ABd, =18.1 Hz), 2.29 (2H, m), 1.88-1.63 (2H, m), and 1.44 (9H, s). m/z (ES+) 332 (M+l).
PREPARATION 5 (5i?,6g)-3-Trifluoromethylsulfonyloxy-6-phenyl-l-oxa-7-(t.βr^- butoxycarbonvDaza-spiro[4.5]dec-3-ene
To a cooled (-80 °C) solution of 1M sodium hexamethyldisilazide (0.38ml, 0.38mmol) in THF was added a solution of (5i?,6S)-3-keto-6- phenyl-l-oxa-7-(t.er -butoxycarbonyl)aza-spiro[4.5]decane (Preparation 4; O.lOδmg, 0.319mmol) in THF (3ml). The solution was stirred for 1 hours at -80°C then a solution of 2-[N,N-bis(trifluoromethylsulfonyl)amino]-5- chloropyridine (0.163g, 0.415mmol) in THF (3ml) was added. The solution was stirred at -80°C for 30 minutes then at room temperature for 30 minutes before being quenched by addition of saturated ammonium chloride solution and ethyl acetate. The dried (MgSO4) organic phase was purified by chromatography on a column containing silica gel (eluting with hexane containing increasing proportions of ethyl acetate between 0% to 5%). Evaporation of the fractions gave the title compound. :H NMR (360MHz, CDC13) δ 7.4 (2H, d, =7.3 Hz), 7.3-7.22 (3H, m), 6.01 (IH, t, =2.13 Hz), 5.13 (IH, s), 4.56 and 4.26 (2H, ABdd, J=12.4, 1.97 Hz),4.10 (IH, dt, =12.6, 4.22 Hz), 3.00 (IH, m), 2.28-2.04 (2H, m), 1.88-1.76 (2H, m), and 1.37 (9H, s). m/z (ES+) 464 (M+l).
PREPARATION 6
(5i?,65)-3-Trimethylstannyl-6-phenyl-l-oxa-7-(tβr^-butoxycarbonyl)aza- spiro[4.5]dec-3-ene
To a degassed solution of (δ/^βiS^-S-trifluoromethylsulfonyloxy-β- phenyl-l-oxa^-^er^butoxycarbony^aza-spirol δ^ec-S-ene (Preparation 5; 0.482g, 1.04mmol), lithium chloride (0.264g, 6.25mmol), lithium carbonate (0.076g) and hexamethyl distannane(0.96g, 2.9mmol) in THF (10ml) was added triphenylphosphine palladium (0) (0.06g). The solution was degassed and then heated at 60°C for 5 hours under nitrogen. Water (20ml) and ethyl acetate (20ml) were added and the dried organic phase was purified by chromatography on a column containing silica gel (eluting with hexane containing increasing proportions of ethyl acetate between 0% to 5%). Evaporation of the fractions gave the title compound as a crystalline solid. Η NMR (360MHz, CDCI3) δ 7.25 (2H, d, =7.3 Hz), 7.1- 7.0 (3H, m), 5.83 (IH, t, =2.5 Hz), 4.78 (IH, s), 4.48 and4.02 (2H, dd, =12.9, 2.3 Hz), 3.96 (IH, dd, =6.16, 13.4 Hz), 2.95 (IH, td, =13.3, 4.5 Hz), 1.84 (IH, m), 1.68 (IH, m), 1.60 (2H, m), 1.19 (9H, s), and 0.0 (6H, s).
PREPARATION 7 (25,,3J?)-l-t.ert-Butoxycarbonyl-3-(3-hydroxypropyn-l-yl)-2-phenylpiperidin- 3-ol
O-Trimethylsilylpropargyl alcohol (24.51ml, 20.47g, 160ml) was added slowly to a cooled (-10°C) solution of ethylmagnesium bromide (IM in tetrahydrofuran, 160ml, 160mmol). The mixture was stirred at 0°C for 20 minutes, then at room temperature for 2 hours. The mixture was cooled to -10°C and a solution of (2S)-l-ter£-butoxycarbonyl-2- phenylpiperidin-3-one (Preparation 1; 42.3g) in tetrahydrofuran (200ml) was added dropwise over 30 minutes. (Internal temperature below -δ°C). δ The mixture was stirred at room temperature for 14 hours, poured into water (300ml) and saturated aqueous ammonium chloride (300ml) and extracted with ethyl acetate (2x300ml). The combined organic fractions were washed with brine (300ml), dried (MgSO ) and the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl 0 acetate (δOOml) and a solution of tetrabutylammonium fluoride (IM in THF, 160ml, lβOmmol) was added dropwise. The mixture was stirred at room temperature for 30 minutes, water (300ml) was added, and the layers were separated. The aqueous layer was extracted with ethyl acetate (2x300ml) and the combined organic fractions were washed with 5 water (300ml) and brine (300ml), dried (MgSO4) and the solvent was evaporated under reduced pressure to give the crude title compound as an orange oil (45g). The crude material was purified by flash column chromatography on silica gel, eluting with hexane/ethyl acetate (90:10 increasing to 2δ:7δ) to give the title compound as an amber oil (32.2g). Η 0 NMR (CDC13) δ 7.δ3-7.δδ (2H, m), 7.19-7.3δ (3H, m), δ.δ6 (IH, s), 4.27 (2H, s), 3.99-4.03 (IH, m), 3.2δ (IH, br s), 2.77-2.81 (IH, m), 2.77 (IH, br s), 2.12-2.20 (IH, m), 1.91-1.99 (2H, m), 1.77-1.83 (IH, m), and 1.39 (9H, s).
PREPARATION 8 δ 2-Bromo-4-(trifluoromethoxy)phenol
To a cooled (0 °C) solution of 4-trifluoromethoxyphenol (3δ.6g, 0.2mol) in chloroform (280ml) was added dropwise a solution of bromine (32g, 0.2mol) in chloroform (δOml). The solution was stirred at 0°C for 1 hour and at room temperature for 2 hours. Dichloromethane (200ml) and 0 water (400ml) ware added and the organic phase was washed further with water(400ml), brine (200ml) and dried (MgSO4). The solvent was removed and the residue was purified by distillation at reduced pressure to give the title compound. Η NMR (2δOMHz, CDC13) δ 7.38 (IH, d, =2.1 Hz), 7.13 (IH, dd, J=9.l, 2.1 Hz), 7.03 (IH, d, =9.1 Hz), and 5.53 (IH, s).
5 PREPARATION 9
2-Benzyloxy-δ-(trifluoromethoxy)bromobenzene
2-Bromo-4-(trifluoromethoxy)phenol (Preparation 8; 5g, 20mmol) was dissolved in ΛT,Λ -dimethylformamide (60ml), and potassium carbonate (5.4g, 40mmol) was added, followed by benzyl bromide (3.5ml, 30mmol),
10 and the reaction was stirred at ambient temperature for 15 hours. The reaction was diluted with water (150ml) and extracted into ethyl acetate (3x60ml). The combined organic fractions were washed with water (100ml), brine (100ml), dried (MgSO ) and evaporated in vacuo. Purification on silica, eluting with 2% and 5% ethyl acetate in hexane gave lδ the title compound as a clear oil (6.7g, 96%). Η NMR (2δ0MHz, CDCI3) δ δ.47 (2H, s), 7.23 (IH, d, J=9 Hz), 7.43 (IH, dd J=8.2, 2.9 Hz), and 7.7δ (6H, m).
20 PREPARATION 10 -(2g.3i?)-l-ter^-Butoxycarbonyl-3-(3-hvdroxyprop-l-en-l-yl)-2- phenylpiperidin-3-ol
Palladium on calcium carbonate, poisoned with lead (Lindlar catalyst, 2g) was added to a solution of (2ιS,3.R)-l-tert-butoxycarbonyl-3-(3- 2δ hydroxypropyn-lyl)-2-phenylpiperidin-3-ol (Preparation 7; 32g, 96.6mmol) in ethyl acetate (300ml) and the mixture was stirred under hydrogen (1 atmosphere) for 4 hours. The mixture was filtered and the solvent was evaporated under reduced pressure to give the title compound as an oil (32g, 100%). iH NMR (360MHz, CDCI3) δ 7.42 (2H, d, J=7.6 Hz), 7.3δ-7.2δ
30 (3H, m), δ.83 (IH, d, 12.3 Hz), δ.68 (IH, dt, =12.3, 6.0 Hz), δ.06 (IH, s), - lo -
4.27 (IH, m), 4.12 (2H, m), 3.32 (IH, m), 3.13 (IH, s), 2.28 (IH, t, J=δ.9 Hz), 2.02 (IH, m), 1.92-1.78 (3H, m), and 1.32 (9H, s). m/z (ES+) 334 (M+l).
PREPARATION 11 δ (δi?.6ιg)-6-Phenyl-l-oxa-7-(t-βr^-butoxycarbonyl)aza-spiror4.δ]dec-3-ene Diethylazodicarboxylate (18.2ml, llδmmol) in THF (100ml) was added dropwise to a solution of -(2<S,3i?)-l-t.ert.-butoxycarbonyl-3-(3- hydroxyprop-l-en-l-yl)-2-phenylpiperidin-3-ol (Preparation 10; 32g, 96mmol) and triphenylphosphine (30.2g, llδmmol) in THF (700ml). The
10 mixture was stirred at 0°C for 30 minutes then at room temperature for 1.5 hours. The solvent was evaporated under reduced pressure and the residue was purified by flash column chromatography on silica gel, eluting with hexane/ethyl acetate (95:δ increasing to 80:20) to give the title compound as a colorless solid (23.4g, 77%). Η NMR (CDCla) δ 7.4δ (2H, d, lδ =7.4 Hz), 7.27 (2H, t, =7.4 Hz), 7.20 (IH, t, =7.4 Hz), 6.03 (IH, dt, =6.1, 2.0 Hz), 5.68 (IH, dt, =6.1, 2.0 Hz), 5.06 (IH, s), 4.61 (IH, dt, =13.1, 2.0 Hz), 4.32 (IH, dt, =13.1, 2.0 Hz), 4.08 (IH, m), 3.05 (IH, m), 2.05 (IH, m), 1.75 (3H, m), and 1.37 (9H, s). m/z (ES+) 316 (M+l).
20 PREPARATION 12
2-Benzyloxy-5-(trifluoromethoxy)benzene
Benzyl bromide (66.17ml, 9δ.3δg, O.δ6mol) was added to a mixture of 4-(trifluoromethoxy)phenol (90.26g, O.δlmol) and potassium carbonate (140.97g, 1.2mol) in dimethylformamide (160ml) and the mixture was
2δ stirred at room temperature for 72 hours. The mixture was poured into water (1.5 1) and extracted with ethyl acetate (3x500ml). The combined organic fractions were washed with aqueous sodium carbonate (saturated, δOOml), dried (MgSO ) and the solvent was evaporated under reduced pressure to give the title compound as a colorless solid (133. δg, 99%). *H
30 NMR (360MHz, CDCI3) δ 7.39 (δH, m), 7.14 (2H, d, =9.0 Hz), 6.9δ (2H, d, =9.0 Hz), and δ.Oδ (2H, s). PREPARATION 13
2-Benzyloxy-δ-(trifluoromethoxy)iodobenzene
Iodine (71.96g, 0.28mol) in chloroform was added dropwise to a δ mixture of 2-benzyloxy-δ-(trifluoromethoxy)benzene (Preparation 12, 73.06g, 0.27mol) and silver trifluoroacetate (71.δ7g, 0.32mol) in dichloromethane and the mixture was stirred at room temperature for 18 hours. The mixture was filtered through celite, washed with aqueous sodium thiosulfate (δ%, 2x2 1), dried (MgSO ) and the solvent was
10 evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/ethyl acetate, to give the title compound as a colorless oil (108.03g), containing 11% unreacted 2-benzyloxy-δ-(trifluoromethoxy)iodobenzene. Η NMR (360MHz, CDCI3) δ 7.67 (IH, d, =2.8 Hz), 7.40 (δH, m), 7.16 (IH, dd, lδ =8.9, 2.8 Hz), 6.82 (IH, d, =8.9 Hz), and δ.14 (2H, s).
PREPARATION 14
(δ_R,65)-3-(2-Benzyloxy-δ-(trifluoromethoxy)phenyl)-6-phenyl-l-oxa-7-(t,er^- butoxycarbonyl)aza-spiror4.δ"|dec-3-ene
20 (δ£,6S)-3-Trimethylstannyl-6-phenyl-l-oxa-7-(teri- butoxycarbonyl)aza-spiro[4.δ]dec-3-ene (Preparation 6; 6.43mmol), lithium chloride (0.163g), benzyloxy-δ-(trifluoromethoxy)phenol (Preparation 9; 7.7mmol) in toluene (2δml) was degassed before addition of triphenylphosphine palladium (0) (0.37g). The solution was degassed
2δ thoroughly before heating to 110°C for 14 hours. The solution was partitioned between water and ethyl acetate and the dried organic phase was purified by chromatography on a column containing silica gel (eluting with hexane containing increasing proportions of ethyl acetate between 0% to 4%) to give the title compound. Η NMR (360MHz, CDCI3) δ 1.33 (9H,
30 s), 1.65 (IH, m), 1.76 (2H, m), 2.08 (IH, m), 3.11 (IH, m), 4.08 (IH, m),
4.60 (IH, dd, J=12.2 Hz, J=2 Hz), 4.92 (IH, dd, J=12.1 Hz, =1.8 Hz), 5.08 (IH, s), δ.l (2H, q, =11.5 Hz), 6.6δ (IH, s), 6.94 (2H, d, J=8.9 Hz), 7.08 (IH, d, =9 Hz), 7.18 (2H, t, =8.1 Hz), 7.2δ (3H, m), 7.38 (δH, m).
PREPARATION 15 δ (3S'.δ R.65)-3-(2-Hvdroxy-δ-(trifluoromethoxy)phenyl)-6-phenyl-l-oxa-7- (t.er -butoxycarbonyl)aza-spiro[4.δ1decane
(δ/^,6S)-3-(2-Benzyloxy-δ-(trifluoromethoxy)phenyl)-6-phenyl-l-oxa- 7-(t.ert.-butoxycarbonyl)aza-spiro[4.δ]dec-3-ene (Preparation 14) (3.88g) was dissolved in ethyl acetate (15ml) and methanol (15ml). Palladium
10 hydroxide on carbon (l.OOg) was added and the suspension was shaken under a hydrogen atmosphere (50 psi) for 72 hours. The mixture was filtered and the solvent was evaporated under reduced pressure. The residue was purified by medium pressure chromatography on silica gel, eluting with hexane/ethyl acetate (75:2δ) to give (3R,5R,6S)-3-(2-hydroxy- lδ 5-(trifluoromethoxy)phenyl)-6-phenyl-l-oxa- 7-(tert-butoxycarbonyl)aza- spiro[4.5]decane (191mg), Η NMR (2δOMHz, CDCI3) δ 7.70 (2H, d, =7.3 Hz), 7.33 (2H, t, J=7.3 Hz), 7.26 (IH, d, =7=7.3 Hz), 7.0δ (IH, br s), 6.96 (2H, m), 6.82 (IH, d, =9.4 Hz), δ.43 (IH, s), 4.27 (IH, m), 4.01 (IH, m), 3.9δ (IH, m), 3.73 (IH, m), 2.73 (2H, m), 2.33 (IH, m), 1.87-1.68 (4H, m);
20 and l.δO (9H, s).and (3S,5R,6S)-3-(2-hydroxy-5-(trifluoromethoxy)phenyl)- 6-phenyl-l-oxa- 7-(tert-butoxycarbonyl)aza-spiro[4.5]decane (2.3g), Η NMR (360MHz, CDCI3) δ 1.38 (9H, s), 1.73 (2H, m), 1.81 (IH, m), 2.18 (2H, m), 2.δ0 (IH, m), 2.81 (IH, m), 3.62 (IH, t, =7.2 Hz), 3.92 (IH, m), 3.98 (IH, d, =13.2 Hz), 4.23 (IH, m), δ.33 (IH, s), 6.7δ (IH, d, =8.δ Hz), 6.94 (2H,
2δ m), 7.2δ (IH, m), 7.31 (2H, m), and 7.δδ (2H, d, J=7.8 Hz).
PREPARATION 16
(3i?,δ ,65)-3-(2-Benzyloxy-δ-(trifluoromethoxy)phenyl)-6-phenyl-l-oxa-7- (ter^-butoxycarbonyl)aza-spiror4.δldecane 30 A mixture of 2-benzyloxy-δ-(trifluoromethoxy)iodobenzene
(Preparation 13, 21.8g, 55.2mmol), (5Λ,6<S -6-phenyl-l-oxa-7-(ter«- butoxycarbonyl)aza-spiro[4.5]dec-3-ene (Preparation 11, 7.0g, 22.1mmol), tetra-n-butylammonium chloride (6.18g, 22.2mmol), lithium chloride (9.35g, 0.22mol) and potassium formate (δ.64g, 67.0mmol) in dimethylformamide (100ml) was degassed with a firestone valve (δ x). δ Palladium acetate (491mg, 2.2mmol) was added and the mixture was degassed with a firestone valve (δ x). The mixture was stirred at 60°C for lδ hours, then further 2-benzyloxy-δ-(trifluoromethoxy)iodobenzene (Preparation 13, 4.32g, ll.Ommol), potassium formate (2.78g, 33.δmmol) and palladium acetate (260mg, l.lmmol) were added. The mixture was
10 stirred at 60°C for 22 hours, cooled and filtered. The solvent was evaporated under reduced pressure, water (600ml) was added and the mixture was extracted with ethyl acetate (2x300ml). The combined organic fractions were washed with brine (300ml), dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified lδ by flash column chromatography on silica gel, eluting with hexane/dichloromethane (75:25 increasing to 0:100) then dichloromethane/ethyl acetate (95:δ), to give the title compound (9.42g, 73%). iH NMR (360MHz, CDC13) δ 7.δ6 (2H, d, =7.7 Hz), 7.40-7.20 (8H, m), 7.14 (IH, d, =2.0 Hz), 7.00 (IH, dd, =8.9, 2.0 Hz), 6.88 (IH, d, J=8.9 0 Hz), δ.30 (IH, s), δ.08 (2H, s), 4.27 (IH, m), 3.97 (IH, m), 3.87 (2H, m), 2.78 (IH, m), 2.δ6 (IH, m), 2.15 (IH, m), 1.96 (IH, m), 1.67 (3H, m), and 1.42 (9H, s).
PREPARATION 17
25 (3 .5JR.65')-3-(2-Hvdroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-l-oxa-7-
(t,gr^-butoxycarbonyl)aza-spiro[4.δldecane
Palladium on carbon (10%, 0.δ9g) was added to a solution of
(3i?,δi?,6S)-3-(2-benzyloxy-δ-(trifluoromethoxy)phenyl)-6-phenyl-l-oxa-7-
(£er£-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 16, 6.10g, 30 lO.δmmol) in methanol-water (99:1, 200ml) and the mixture was stirred under hydrogen (δO psi.) for 72 hours. The mixture was filtered, washing with ethanol, and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with dichloromethane/ethyl acetate (99:1 increasing to 90:10) to give the title compound. Η NMR (360MHz, CDC1 ) δ 7.70 (2H, d, ,7=7.3 δ Hz), 7.33 (2H, t, =7.3 Hz), 7.26 (IH, d, =7.3 Hz), 7.0δ (IH, br s), 6.96 (2H, m), 6.82 (IH, d, J=9.4 Hz), δ.43 (IH, s), 4.27 (IH, m), 4.01 (IH, m), 3.9δ (IH, m), 3.73 (IH, m), 2.73 (2H, m), 2.33 (IH, m), 1.87-l.δ8 (4H, m), and l.δO (9H, s).
0 PREPARATION 18
(3,g.δi?,6g -3-r2-(l-Phenylthiocvcloprop-l-yl)oxy-δ- (trifluoromethoxy)phenyn-6-phenyl-l-oxa-7-(^gr^-butoxycarbonyl)aza- spiro [4. δ] decane
(3S',δ ,6»S)-3-(2-Hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-l- 5 oxa-7-(£er£-butoxycarbonyl)aza-spiro[4.δ]decane (Preparation lδ) (290mg, O.δ9mmol) was dissolved in toluene (δml) and silver carbonate (179mg, 0.6δmmol) was added in one portion. (l-Iodocycloprop-l-yl)phenylsulfide (Cohen T. and Matz J. R., J. Am. Chem. Soc. 1980, 102, 6902) (180mg, 0.6δmmol) was then added over one minute at room temperature. The 0 mixture was stirred at δδ°C for 4 hours, then further portions of silver carbonate (179mg, 0.6δmmol) and (l-iodocycloprop-l-yl)phenylsulfide (180mg, 0.6δmmol) were added. The mixture was stirred at δδ°C for a further 3 hours, cooled, filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on 5 silica gel, eluting with hexane/ethyl acetate (90:10 increasing to 80:20) to give the title compound as a colourless oil (120mg, 32%). Η NMR (250MHz, CDCI3) δ 7.65-7.44 (4H, m), 7.36-7.23 (7H, m), 7.13-7.02 (2H, m), δ.16 (IH, br s), 4.09 (IH, t, =6 Hz), 4.03-3.92 (IH, m), 3.67-3.49 (2H, m), 2.94-2.79 (IH, m), 2.26 (IH, dd, J=7.9, 12.9 Hz), 2.1δ-2.01 (2H, m), 1.76- 0 1.59 (3H, m), 1.53-1.4δ (4H, m), and 1.36 (9H, s). m/z (ES+) 642 (M+l). " Zυ ~
PREPARATION 19
(3.R,5.R.6S -3-r2-(l-Phenylthiocvcloprop-l-yl)oxy-5- (trifluoromethoxy)phenyll-6-phenyl-l-oxa-7-(t-grt.-butoxycarbonyl aza- spiror4.5]decane δ Prepared from (3i?,δi?,6S)-3-(2-hydroxy-δ-
(trifluoromethoxy)phenyl)-6-phenyl-l-oxa-7-(t.eri-butoxycarbonyl)aza- spiro[4.δ]decane (Preparation 17) according to the method of Preparation 18. iH NMR (360MHz, CDC13) δ 7.δ7 (2H, app. d, =7.6 Hz), 7.4δ (2H, app. d, =7.7 Hz), 7.36-7.19 (7H, m), 7.16-7.06 (2H, m), δ.28 (IH, br s), 10 4.13 (IH, app. t, J=7.8 Hz), 3.96 (IH, br. d, =13 Hz), 3.80-3.60 (2H, m), 2.79 (IH, br. t, =13 Hz), 2.δ0 (IH, dd, =13, 7.9 Hz), 2.17 (IH, dt, =13, 4.6 Hz), 1.80 (IH, dd, J=12, 9.8 Hz), 1.7δ-1.38 (7H, m), and 1.44 (9H, s). m/z (ES+) 642 (M+l).
lδ PREPARATION 20
(3S',δ-R,65r)-3-[2-Cyclopropoxy-5-(trifluoromethoxy)phenyll-6-phenyl-l-oxa- 7-(£βr£-butoxycarbonyl)aza-spiro|"4.δ"|decane
Naphthalene (120mg, 0.936mmol) was dissolved in THF (1.5ml) under nitrogen and freshly cut lithium metal (7.0mg, 0.94mmol) was
20 added. The mixture was then sonicated at room temperature for 20 minutes to produce a dark green solution of lithium naphthalenide. This solution was cooled to -78 °C, then (3S,5i?,6S)-3-[2-(l-phenylthiocycloprop- l-yl)oxy-5-(trifluoromethoxy)phenyl]-6-phenyl-l-oxa-7-(t.eri- butoxycarbonyl)aza-spiro[4.δ]decane (Preparation 18) (120mg, 0.187mmol)
2δ in THF (O.δml) was added over 1 minute. The reaction mixture was stirred for 30 minutes, then water (5ml) and ether (10ml) were added. The layers were separated and the aqueous layer was extracted with ether (10ml). The combined organic fractions were dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified
30 by column chromatography on silica gel, eluting with hexane/ethyl acetate (90:10 increasing to 80:20) to give the title compound as a colourless oil (δ8.6mg, 69%). Η NMR (260MHz, CDC13) δ 7.68-7.62 (2H, m), 7.36-7.17 (4H, m), 7.10-7.01 (2H, m), 5.18 (IH, br s), 4.20 (IH, t, ,7=6.7 Hz), 4.05-3.96 (IH, m), 3.76-3.55 (3H, m), 2.92-2.79 (IH, m), 2.37 (IH, dd, ,7=12.9, 7.8 Hz), 2.18-2.06 (2H, m), 1.80-1.67 (3H, m), 1.38 (9H, s), and 0.86-0.73 (4H, m). m/z (ES+) 634 (M+l).
PREPARATION 21
(3i?,5it!,65r)-3-r2-Cvclopropoxy-δ-(trifluoromethoxy)phenyl]-6-phenyl-l-oxa- 7 - (ter -butoxycarbonvD aza-spiro \4.51 decane Naphthalene (120mg, 0.936mmol) was dissolved in THF (1.5ml) under nitrogen and freshly cut lithium metal (7.0mg, 0.94mmol) was added. The mixture was then sonicated at room temperature for 20 minutes to produce a dark green solution of lithium naphthalenide. A solution of (3i2,5#,6S)-3-[2-(l-phenylthiocycloprop-l-yl)oxy-δ- (trifluoromethoxy)phenyl]-6-phenyl-l-oxa-7-(teri-butoxycarbonyl)aza- spiro[4.5]decane (Preparation 19, 135mg, 0.21mmol) in THF (2ml) under nitrogen was cooled to -78°C and the solution of lithium naphthalenide in THF was added dropwise until the intense green colour persisted. The reaction was then stirred for one minute, water (δml) was added and the mixture was warmed to room temperature. Ether (10ml) was added and the layers were separated. The aqueous phase was extracted with a further portion of ether (10ml) and the combined organic phases were dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with hexane/ethyl acetate (50:60) to give the title compound as a colourless oil (87mg, 78%). *H NMR (360MHz, CDCI3) δ 7.69 (2H, app. d, ,7=7.6 Hz), 7.32 (2H, app. t, ,7=7.6 Hz), 7.27-7.18 (2H, m), 7.11-7.03 (2H, m), δ.32 (IH, br s), 4.29-4.21 (IH, m), 3.97 (IH, br. d, ,7=13 Hz), 3.83-3.68 (3H, m), 2.76 (IH, dt, ,7=13, 4.1 Hz), 2.55 (IH, dd, ,7=13, 7.2 Hz), 2.22 (IH, dt, J=12, 5.2 Hz), 1.86 (IH, dd, ,7=13, 9.9 Hz), 1.80-1.63 (3H, m), 1.46 (9H, s), and 0.82- 0.76 (4H, m). m/z (ES+) 534 (M+l). COMPOUND A
(35,,5i?,65l)-3-r2-Cvclopropoxy-δ-(trifluoromethoxy)phenvn-6-phenyl-l-oxa- 7-aza-spiro[4.δldecane Hydrochloride Trifiuoroacetic acid (2.5ml) was added dropwise to a stirred, cooled
0°C) solution of (3S',5i?,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]- 6-phenyl-l-oxa-7-(fert--butoxycarbonyl)aza-spiro[4.5]decane (Preparation 20; 492mg, 0.92mmol) in dichloromethane (25ml) and the mixture was stirred at room temperature for 3 hours. The mixture was poured into water (50ml), the pH was adjusted to 10.0 with aqueous sodium hydroxide (4M) and the mixture was extracted with dichloromethane (3x50ml). The combined organic fractions were dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with dichloromethane/methanol/ammonia (aq.) (96:4:0.4 increasing to 94:6:0.6). The residue was dissolved in ethanol (20ml), cooled in ice and ethereal hydrogen chloride (IM, 1.8ml, 1.8mmol) was added dropwise. The mixture was stirred at 0°C for 5 minutes, then the solvent was evaporated under reduced pressure. The residue was crystallized from ether (20ml)/ethanol (0.5ml) and the solid was collected and dried in vacuo to give the title compound as a colorless solid (354mg, 89%). m.p. 214-216 °C, Η NMR (500MHz, CD3OD) δ 7.59 (2H, m), 7.52 (3H, m), 7.26 (IH, d, ,7=8.9 Hz), 7.03 (IH, dd, ,7=8.9, 2.2 Hz), 6.20 (IH, d, ,7=2.2 Hz), 4.85 (2H, br s), 4.43 (IH, s), 4.19 (IH, t, ,7=8.0 Hz), 3.87 (IH, quin, ,7=8.0 Hz), 3.76 (IH, m), 3.44 (IH, m), 3.25 (2H, m) 2.29-1.78 (6H, m), 0.80 (2H, m), and 0.66 (2H, m). m/z (ES+) 434 (M+l). Found: C, 61.41; H, 5.51; N, 3.08. C24H26F3NO3.HCI requires: C, 61.34; H, 5.79; N, 2.98%. COMPOUND B
(3J?.57:?,6S)-3-r2-Cvclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-l-oxa- 7-aza-spiror4.51decane
Prepared from the compound of Preparation 21 according to the method used for Compound A. Η NMR (360MHz, CDC13) δ 7.50-7.42 (2H, m), 7.36-7.26 (3H, m), 7.03 (IH, d, ,7=8.9 Hz), 6.95 (IH, br. d, ,7=8.9 Hz), 6.81 (IH, br s), 3.92 (IH, t, ,7=7.4 Hz), 3.62-3.63 (2H, m), 3.50 (IH, s), 3.20 (IH, dd, =12, 4.2 Hz), 2.77 (IH, dt, ,7=12, 2.8 Hz), 2.30-1.93 (4H, m), 1.87 (IH, br s), 1.71-1.49 (3H, m), 0.76-0.65 (2H, m), and 0.65-0.64 (2H, m). m/z (ES+) 434 (M+l).
A further compound and diastereomers thereof of use in the present invention may be prepared according to the following method:
DESCRIPTION 1 2-(l-Phenylthiocvcloprop-l-yl)oxy-5-(trifluoromethoxy)benzaldehvde Silver carbonate (1.2 g, 4.34 mmol) was added to a solution of 2-hydroxy-δ-(trifluoromethoxy)benzaldehyde (0.5 g, 2.43 mmol) and (l-iodocycloprop-l-yl)phenylsulfide (Cohen T. and Matz J. R., J. Am. Chem. Soc. 1980, 102, 6902) (1.2 g, 4.34 mmol) in toluene (30 mL) and the mixture was stirred at 40 °C overnight. The mixture was cooled, diluted with ethyl acetate and filtered, washing well with ethyl acetate. The mixture was washed with aqueous sodium hydroxide, dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/Et2θ (95:δ), to give the title compound as a yellow oil (191 mg, 27%). Η NMR (360MHz, CDCI3) δ 1.51-1.66 (2H, m), 1.44-1.48 (2H, m), 7.25-7.35 (7H, m), 7.69 (IH, d, J 2.0 Hz), and 10.26 (IH, s). DESCRIPTION 2
2-Cvclopropoxy-5-(trifluoromethoxy)benzaldehyde
Freshly cut lithium metal (97 mg, 13.9 mmol) was added to a solution of naphthalene (1.77 g, 13.9 mmol) in THF (20 mL) and the δ mixture was sonicated at room temperature for 30 min. to produce a dark green solution of lithium naphthalenide. A solution of 2- ( 1 -phenylthiocycloprop - 1 -yl)oxy- δ- (trifluoromethoxy)benzaldehy de (Description 1, 96 mg, 0.27 mmol) in THF (2 mL) was cooled to -78 °C and the solution of lithium naphthalenide in THF (2 mL) was added dropwise
10 until the intense green colour persisted. The reaction was then stirred for δ min., water (6 mL) was added and the mixture was warmed to room temperature. The mixture was extracted with ethyl acetate, the combined organic fractions were dried (MgSO ) and the solvent was evaporated under reduced pressure. The residue was purified by flash column lδ chromatography on silica gel, eluting with hexane/Et2θ (80:20), to give to give the title compound as a colourless oil (4 mg, 6%). Η NMR (360MHz, CDCI3) δ 0.86 (4H, m), 3.82-3.9 (IH, m), 7.42 (2H, m), 7.62 (IH, d, 2.5 Hz), and 10.36 (IH, s).
20 DESCRIPTION 3
2-Nitro-4-(trifluoromethoxy)phenol
Iron(lll)nitrate nonahydrate (1.97 g, 4.87 mmol) was added to a solution of 4-(trifluoromethoxy)phenol (2 g, 11.24 mmol) in ethanol (20 mL) and the mixture was heated under reflux overnight. The mixture was
2δ allowed to cool to room temperature, acidified to pH 1 with aqueous hydrochloric acid (IM) and extracted with ethyl acetate. The combined organic fractions were dried (MgSO4), and the solvent was evaporated under reduced pressure. The residue was purified by short column chromatography on silica gel, eluting with hexane/EtOAc (70:30), to give
30 the title compound as a yellow oil (2.25 g, 89%). Η NMR (360MHz, CDCI3) δ 10.53 (IH, s), 8.01 (IH, d, ,7 3.0 Hz), 7.49 (IH, dd, ,79.1, 3.0 Hz), and 7.23 (IH, d, J 9.1 Hz).
DESCRIPTION 4
2-(l-Phenylthiocycloprop-l-yl)oxy-5-(trifluoromethoxy)nitrobenzene Prepared from the compound of Description 3 according to the method of Description 1. *H NMR (360MHz, CDC1 ) δ 7.73 (IH, d, ,72.7 Hz), 7.68 (IH, d, 9.2 Hz), 7.50-7.24 (6H, m), 1.57-1.53 (2H, m), and 1.44-1.40 (2H, m).
DESCRIPTION 5
2-Cvclopropoxy-5-(trifluoromethoxy)benzeneamine
Prepared from the compound of Description 4 according to the method of Description 2. Η NMR (360MHz, CDCI3) δ 7.06 (IH, dd, 2.8, 6.7 Hz), 6.66 (2H, m), 3.83 (2H, br s), 3.74 (IH, m), and 0.79 (4H, m). m/z (ES+) 234 (M+l).
DESCRIPTION 6
2-(l-Phenylthiocycloprop-l-yl)oxy-5-(trifluoromethoxy)benzeneamine Iron powder (13.6 g, 241 mmol) was added to a suspension of
2-(l-phenylthiocycloprop-l-yl)oxy-5-(trifluoromethoxy)nitrobenzene (Description 4, 11.27 g, 30.1 mmol) in water (300 mL) and acetic acid (7δ mL) and the mixture was stirred at 80 °C overnight. The mixture was cooled and filtered through celite, washing with ether. The filtrate was extracted with ether, the combined organic fractions were washed with aqueous sodium hydroxide (IM), dried (MgSO4), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/Et2θ (90:10 increasing to 80:20), to give the title compound as a yellow solid (8 g, 78%). Η NMR (360MHz, CDCI3) δ 7.48 (2H, m), 7.34-7.23 (3H, m), 7.15 (IH, d, J 8.74 Hz), 6.60-6.66 (2H, m), 3.78 (2H, br s), 1.49-1.46 (2H, m), and 1.39-1.35 (2H, m).
DESCRIPTION 7
2-Cvclopropoxy-5-(trifluoromethoxy)benzeneamine
Prepared from the compound of Description 6 according to the method of Description 2. Η NMR (360MHz, CDC13) δ 7.06 (IH, dd, 2.8, 6.7 Hz), 6.66 (2H, m), 3.83 (2H, br s), 3.74 (IH, m), and 0.79 (4H, m). m/z (ES+) 234 (M+l).
DESCRIPTION 8
2-Cvclopropoxy-5-(trifluoromethoxy)iodobenzene
An ice-cooled solution of sodium nitrite (3.65 g, 51 mmol) in water (10 mL) was added dropwise to a stirred, cooled (0 °C) solution of 2-cyclopropoxy-5-(trifluoromethoxy)benzeneamine (Description 7, 4.8 g, 20.6 mmol) in aqueous hydrochloric acid (δM, 300 mL), maintaining the internal temperature at 0 °C. The mixture was stirred at 0 °C for 30 min., then potassium iodide (8.65 g, 51.5 mmol) in water (10 mL) was added dropwise, maintaining the internal temperature at 0 °C. The mixture was stirred at 0 °C for 30 min., then allowed to warm up to room temperature and stirred until nitrogen evolution ceased. The mixture was extracted with ether, the organic fraction was washed with aqueous sodium thiosulfate (10%), dried (MgSO4), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/Et2θ (98:2 increasing to 95:6), to give the title compound as a colourless oil (6.23 g, 88%). *H NMR (360MHz, CDCI3) δ 7.62 (IH, d, J 2.4 Hz), 7.20 (IH, dd, J 9.1, 2.4 Hz), 7.15 (IH, d, 9.1 Hz), 3.80 (IH, m), and 0.83 (4H, m). - uU "
DESCRIPTION 9
2-Cyclopropoxy-6-(trifluoromethoxy)benzaldehyde
A solution of 2-cyclopropoxy-5-(trifluoromethoxy)iodobenzene (Description 8, 0.344 g, 1 mmol) in toluene (2.5 mL) was degassed with bubbling nitrogen for 10 min. Tetrakis(triphenylphosphine)palladium (0) (15 mg) was added, the mixture was degassed with bubbling nitrogen for a further 5 min., then carbon monoxide was bubbled through the mixture for 10 min. The mixture was warmed to 50 °C and a solution of tributyl tin hydride (0.3 mL, 1.1 mmol) in toluene (5 mL) was added at a rate of 2 mL/h. via a syringe pump, maintaining carbon monoxide bubbling throughout. The mixture was cooled, diluted with ether (20 mL) and aqueous potassium fluoride solution (50%) was added. The mixture was stirred at room temperature overnight, filtered and the layers were separated. The organic layer was dried (MgSO4), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/Et2θ (80:20), to give the title compound as a colourless oil. Η NMR (360MHz, CDC13) δ 0.86 (4H, m), 3.82-3.9 (IH, m), 7.42 (2H, m), 7.62 (IH, d, 2.5 Hz), and 10.36 (IH, s).
DESCRIPTION 10 (±)-(2iϊ5r)-l-t6r^-Butoxycarbonyl-2-phenylpiperidin-3-one
Dimethyl sulfoxide (32.0 mL, 35.3 g, 0.45 mol) in dichloromethane (100 mL) was added dropwise to a cooled (-70 °C) solution of oxalyl chloride (18.7 mL, 27.5 g, 0.22 mol) in dichloromethane (1000 mL). The mixture was stirred at -70 °C for 15 min., then
(2iS,3iS)-l-t.erf-butoxycarbonyl-3-hydroxy-2-phenylpiperidine (prepared by the method described in European Patent Specification number 0 528 495-A; 50 g, 0.18 mol) in dichloromethane (150 mL) was added dropwise. The mixture was stirred at -70 °C for 1 h., then triethylamine (125.8 mL, 91.3 g, 0.9 mol) was added slowly. The mixture was stirred at room temperature for 1 h., water (250 mL) and aqueous sodium hydrogen carbonate (saturated, 250 mL) were added and the mixture was stirred at room temperature overnight. The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 300 mL). The combined organic fractions were washed with brine, dried (MgSO ) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/EtOAc (90:10), to give the title compound as a yellow oil (45.0 g, 91%). Η NMR (250MHz, CDCls) δ 7.6-7.3 (5H, m), 5.8 (IH, br s), 4.2 (IH, br s), 3.4 (IH, m), 2.6 (2H, ), 2.0 (2H, m), and 1.54 (9H, s).
DESCRIPTION 11
(±)-(2.R3ig.2lS'35,)-l-(^r^-Butoxycarbonyl)-2-phenylpiperidin-3-amine A solution of hydroxylamine hydrochloride (17 g, 0.24 mol) and sodium acetate (55.67 g, 0.41 mol) in water (150 mL) was added to a solution of (±)-(2i?S)-l-iert.-butoxycarbonyl-2-phenylpiperidin-3-one (Description 10, 45 g, 0.16 mol) in ethanol (300 mL) and the mixture was stirred at room temperature for 1 h. The solvent was evaporated under reduced pressure, water was added and the mixture was extracted with ethyl acetate. The organic fraction was washed with brine, dried (MgSO ) and the solvent was evaporated under reduced pressure. The residue was dissolved in ethanol (400 mL) and Raney nickel (50 g) was added. The mixture was shaken under hydrogen (40 psi) overnight, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with CH2Cl2/MeOH (100:0 increasing to 85:15), to give the title compound as a colorless oil (10.9 g, 24%). iH NMR (360MHz, CDCI3) δ 7.43 (2H, d, ,77.0 Hz), 7.30 (3H, m), 5.19 (IH, d, 6.2 Hz), 4.00 (IH, m), 3.17 (2H, m), 1.90-1.64 (4H, m), 1.36 (9H, s), and 1.26 (2H, br s). COMPOUND C
(±)-(2.R3 R.2S3g)-N-{r2-CvclθOropoxy-5-(trifluoromethoxy)phenyl1methyll-2 -phenylpiperidin-3-amine Dihydrochloride
2-Cyclopropoxy-5-(trifluoromethoxy)benzaldehyde (Description 9, 55 mg, 0.21 mmol) was added to (±)-(2-R3JR,2S3S l-(t.eri-butoxycarbonyl)-2- phenylpiperidin-3-amine (Description 11, 68 mg, 0.21 mmol), citric acid (89 mg, 0.42 mmol) and 3A molecular sieves in dry methanol (5 mL) and the mixture was stirred at room temperature for 1.5 h. Sodium borohydride (30 mg) was added and the mixture was stirred at room temperature for 2 h. Ethyl acetate was added and the mixture was washed with aqueous hydrochloric acid (0.1M, 2 x 25 mL) and brine (25 mL), dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was dissolved in dichloromethane (3 mL), cooled to 0 °C and trifluoroacetic acid (2 mL) was added slowly. The mixture was stirred at room temperature for 1 h., the solvent was evaporated under reduced pressure and ethyl acetate was added. The mixture was washed with aqueous sodium hydrogen carbonate (saturated, 2 x 25 mL) and brine (25 mL), dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with CH2Cl2/MeOH/NH3(Aq.) (96:4:0.4). The residue was dissolved in ethanol (2 mL), cooled in ice and ethereal hydrogen chloride (IM, 0.24 mL, 0.24 mmol) was added. The solvent was evaporated under reduced pressure and the residue was recrystallised from ethanol to give the title compound as a colorless solid (20 mg, 20%). m.p. 169-171 °C. Η NMR (400MHz, CD3OD) δ 0.64 (IH, m), 0.80 (3H, m), 1.99 (IH, m), 2.24 (IH, m), 2.46 (2H, m), 3.30 (IH, m), 3.64 (IH, m), 3.75 (2H, m), 3.96 (IH, br s), 4.08 (IH, m), 4.95 (IH, s), 7.23 (IH, s), 7.31 (IH, d, 9.0 Hz), 7.37 (IH, d, 9.0 Hz), 7.64 (3H, m), and 7.67 (2H, m). m/z (ES+) 407 (M+l). Particularly preferred NK-1 receptor antagonists of use in the present invention are compounds which are potent NK-1 receptor antagonists, i.e. compounds with an NK-1 receptor affinity (IC50) of less than lOnM, favourably less than 2nM and preferably less than InM.
The class of orally active, long acting, CNS-penetrant NK-1 receptor antagonists of use in the present invention is identified using a combination of the following assays:
ASSAY 1: NK-1 Receptor binding
NK-1 receptor binding assays are performed in intact Chinese hamster ovary (CHO) cells expressing the human NK-1 receptor using a modification of the assay conditions described by Cascieri et al, J. Pharmacol. Exp. Ther., 1992, 42, 468. Typically, the receptor is expressed at a level of 3xl05 receptors per cell. Cells are grown in monolayer culture, detached from the plate with enzyme-free dissociation solution (Speciality Media Inc.), and washed prior to use in the assay. 125I-Tyr8- substance P (O.lnM, 2000Ci/mmol; New England Nuclear) is incubated in the presence or absence of test compounds (dissolved in 5μl dimethylsulphoxide, DMSO) with δxlO4 CHO cells. Ligand binding is performed in 0.25ml of 50mM Tris-HCl, pH7.δ, containing 5mM MnC-2, lδOmM NaCl, 0.02% bovine serum albumin (Sigma), 50μg/ml chymostatin (Peninsula), O.lnM phenylmethylsulphonyl fluoride, 2μg/ml pepstatin, 2μg/ml leupeptin and 2.8μg/ml furoyl saccharine. The incubation proceeds at room temperature until equilibrium is achieved (>40 minutes) and the receptor-ligand complex is harvested by filtration over GF/C filters pre- soaked in 0.1% polyethylenimine using a Tomtek 96-well harvester. Nonspecific binding is determined using excess substance P (lμM) and represents <10% of total binding.
ASSAY 2: Gerbil Foot-Tapping CNS-penetrant NK-1 receptor antagonists for use in the present invention can be identified by their ability to inhibit foot tapping in gerbils induced by anxiogenic agents (such as pentagastrin) or central infusion of NK-1 receptor agonists such as GR73632, or caused by aversive stimulation such as foot shock or single housing, based on the method of Rupniak & Williams, Eur. J. Pharmacol, 1994, 265, 179. Male or female Mongolian gerbils (35-70g) are anaesthetised by inhalation of an isoflurane/oxygen mixture to permit exposure of the jugular vein in order to permit administration of test compounds or vehicle in an injection volume of δml/kg i.v. Alternatively, test compounds may be administered orally or by subcutaneous or intraperitoneal routes. A skin incision is then made in the midline of the scalp to expose the skull. An anxiogenic agent (e.g. pentagastrin) or a selective NK-1 receptor agonist (e.g. GR73632 (d Ala[L-Pro9,Me-Leu10]-substance P-(7-ll)) is infused directly into the cerebral ventricles (e.g. 3pmol in 5μl i.c.v., depending on test substance) by vertical insertion of a cuffed 27 gauge needle to a depth of 4.5mm below bregma. The scalp incision is closed and the animal allowed to recover from anaesthesia in a clear perspex observation box (25cm x 20cm x 20cm). The duration and/or intensity of hind foot tapping is then recorded continuously for approximately 5 minutes. Alternatively, the ability of test compounds to inhibit foot tapping evoked by aversive stimulation, such as foot shock or single housing, may be studied using a similar method of quantification.
ASSAY 3: Ferret Emesis
Individually housed male ferrets (1.0 -2.5 kg) are dosed orally by gavage with test compound. Ten minutes later they are fed with approximately lOOg of tinned cat food. At 60 minutes following oral dosing, cisplatin (lOmg/kg) is given i.v. via a jugular vein catheter inserted under a brief period of halothane anaesthesia. The catheter is then removed, the jugular vein ligated and the skin incision closed. The ferrets recover rapidly from the anaesthetic and are mobile within 10-20 minutes. The animals are observed continuously during recovery from the - DO -
anaesthetic and for 4 hours following the cisplatin injection, after which time the animals are killed humanely. The numbers of retches and vomits occurring during the 4 hours after cisplatin administration are recorded by trained observers.
ASSAY 4: Separation-Induced Vocalisation
Male and female guinea-pigs pups are housed in family groups with their mothers and littermates throughout the study. Experiments are commenced after weaning when the pups are 2 weeks old. Before entering an experiment, the pups are screened to ensure that a vigorous vocalisation response is reproducibly elicited following maternal separation. The pups are placed individually in an observation cage (5δcm x 39cm x 19cm) in a room physically isolated from the home cage for 15 minutes and the duration of vocalisation during this baseline period is recorded. Only animals which vocalise for longer than 5 minutes are employed for drug challenge studies (approximately 50% of available pups may fail to reach this criterion). On test days each pup receives an oral dose or an s.c. or i.p. injection of test compound or vehicle and is then immediately returned to the home cage with its mother and siblings for 30 to 60 minutes (or for up to 4 hours following an oral dose, dependent upon the oral pharmacokinetics of the test compound) before social isolation for 15 minutes as described above. The duration of vocalisation on drug treatment days is expressed as a percentage of the pre-treatment baseline value for each animal. The same subjects are retested once weekly for up to 6 weeks. Between 6 and 8 animals receive each test compound at each dose tested.
As used herein, the term "CNS-penetrant" refers to NK-1 receptor antagonists which are able to inhibit NK-1 receptor antagonist-induced foot-tapping in the gerbil as hereinafter defined. Essentially, hind foot-tapping in the gerbil induced by infusion of the NK-1 receptor agonist, GR73632 (d Ala[L-Pro9,Me-Leu10] -substance P- - όb -
(7-11)), under anaesthesia, directly into the central ventricles is inhibited when a CNS-penetrant NK-1 receptor antagonist is administered intravenously immediately prior to GR73632 challenge, wherein hind foot- tapping over a period of five minutes following recovery from the anaesthesia is inhibited with an ID5o≤3mg/kg, and preferably with an
Figure imgf000038_0001
In an alternative method, the NK-1 receptor antagonist is administered orally, 1 hour prior to GR73632 challenge, wherein the foot- tapping over a period of five minutes following recovery from anaesthesia is inhibited with an IDso≤30mg/kg, and preferably with an IDso≤lOmg/kg. CNS-penetrant NK-1 receptor antagonists of use in the present ivnention are also effective in the attenuation of separation-induced vocalisations by guinea-pig pups as hereinafter defined.
Essentially, a vocalisation response in guinea-pig pups is induced by isolation from their mothers and littermates, which response is attenuated when a CNS-penetrant NK-1 receptor antagonist is administered subcutaneously 30 minutes prior to isolation, wherein vocalisations during the first 15 minutes of isolation are attenuated with an ID50≤20mg/kg, preferably with an IDso≤lOmg/kg, and especially with an IDso≤δmg/kg. In an alternative method, the NK-1 receptor antagonist is administered orally, 4 hours prior to isolation, wherein vocalisations during the first lδ minutes of isolation are attenuated with an ID5o<20mg/kg, preferably with an IDso≤lOmg/kg, and especially with an IDso≤δmg/kg. A suitable selection cascade for NKi antagonists of use according to the present invention is as follows:
(i) Determine affinity for human NKi receptor in radioligand binding studies (Assay 1); select compounds with IC50 ≤ lOnM, preferably IC50 < 2nM, especially IC50 < InM. - I -
(ii) Determine ability of compounds to penetrate CNS by their ability to inhibit foot tapping in gerbils induced by central injection of an NKi agonist (Assay 2); select compounds that inhibit foot tapping with ID50 < 3mg/kg i.v., and preferably ID50 ≤ l g/kg i.v. when administered immediately prior to central NKi agonist challenge, or ID50 < 30mg/kg p.o., and preferably ID50 ≤ lOmg/kg p.o. 1 hour prior to challenge.
(iii) Determine central duration of action of compounds in gerbil foot tapping assay following intravenous administration 24 hours prior to central NKi agonist challenge; select compounds showing < 26-fold loss of potency compared with ID50 determined in step (ii) above with the proviso that ID50 ≤ lOmg/kg i.v., and preferably < 5mg/kg i.v. after 24 hour pre-treatment.
(iv) Determine oral bioavailability of compounds by pharmacokinetic analysis, activity in gerbil foot tapping assay following oral administration and/or by ability to inhibit cisp latin-induced emesis in ferrets (Assay 3); select compounds with IDg0 < 3mg/kg p.o., and preferably
Figure imgf000039_0001
Particularly preferred compounds of use in the present invention are identified using steps (i) to (iv) followed by step (v): (v) Determine activity of compounds in assays sensitive to conventional antipsychotic drugs (inhibition of distress vocalisations in guinea-pig pups (Assay 4)). Select compounds with ID50 ≤ 20mg/kg, and preferably ID50 ≤ lOmg/kg.
Yet further preferred compounds of use in the present invention may be selected from those compounds which satisfy the NK-1 receptor binding criteria of step (i) which, in addition, have < 5-fold shift in affinity when incubated in the presence of human serum albumin (HSA) to show non-specific protein binding.
One example of a NK-1 receptor antagonist of use in the present invention is the compound 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)- ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-lH,4H-l,2,4-triazolo)methyl)- morpholine, the preparation of which is described in International Patent Specification No. WO 95/16679. In the aforementioned assays, this compound has the following activity:
human NK-1 receptor binding: IC5o=0.1nM gerbil foot-tapping (5 mins.):
Figure imgf000040_0001
i.v. gerbil foot-tapping (24 hrs.): ID5o=0.33mg/kg i.v. ferret emesis: ID9o<3mg/kg p.o. guinea-pig vocalisation (4 hr. pre-treatment): ID5o=0.73mg/kg p.o.
The following example illustrates pharmaceutical compositions according to the invention.
EXAMPLE 1 Tablets containing 50-300mg of NK-1 antagonist
Amount mg
NK-1 antagonist 50.0 100.0 300.0
Microcrystalline cellulose 80.0 80.0 80.0
Modified food corn starch 80.0 80.0 80.0
Lactose 189.5 139.6 139.5
Magnesium Stearate 0.5 0.5 0.6
The active ingredient, cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 50mg, lOOmg and 300mg of the NK-1 receptor antagonist per tablet.

Claims

1. Use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of severe anxiety disorders without concomitant therapy with other anti-anxiety agents.
2. Use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to benzodiazepines or for whom benzodizaepines are contraindicated.
3. Use of an orally active, long acting, CNS penetrant NK-1 receptor antagonist for the manufacture of a medicament adopted for oral administration for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to tricyclic antidepressants or for whom tricyclic antidepressants are contraindicated.
4. Use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to SSRIs or serotonin agonists or antagonists or for whom SSRIs or serotonin agonists or antagonists are contraindicacted.
5. An oral pharmaceutical composition for the treatment of severe anxiety disorders which comprises essentially an orally active, long acting, CNS-penetrant NK-1 receptor antagonist, together with a pharmaceutically acceptable carrier or excipient.
6. A method for the treatment or prevention of severe anxiety disorders without concomitant therapy with other anti-anxiety agents which method comprises the oral administration to a patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.
7. A method for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to benzodiazepines or for whom benzodiazepines are contraindicated, which method comprises oral administration to the patient in need of such treatment of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.
8. A method for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to tricyclic antidepressants or for whom tricyclic antidepressants are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.
9. A method for the treatment or prevention of severe anxiety disorders, without concomitant therapy with other anti-anxiety agents, in a patient who is non-responsive to SSRIs or serotonin agonists or antagonists or for whom SSRIs or serotonin agonists or antagonists are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.
10. A use according to any one of claims 1 to 4, or a composition according to claim 5 or a method according to anyone of claims 6 to 9 wherein the orally active, long acting, CNS-penetrant NK-1 receptor antagonist is selected from the classes of compounds described in EP-A- 0577394, WO-A-9508549, WO-A-9618124, WO-A-9523798, WO-A-9606181 or International Patent Application No. PCT/GB97/01630.
11. A use according to any one of claims 1 to 4, or a composition according to claim 5 or a method according to anyone of claims 6 to 9 wherein the orally active, long acting, CNS-penetrant NK-1 receptor antagonist is:
2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3(S)-(4-fluorophenyl)-4-(3-(5-oxo-
1H, 4H- 1 , 2, 4-triazolo)methy l)morpholine ; 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(3-(5-oxo-lH,4H- l,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;
2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-4-(3-(5-oxo-lH,4H-l,2,4- triazolo)methyl)-3-(S)-phenyl-morpholine;
2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)- 4-(3-(5-oxo-lH,4H-l,2,4-triazolo)methyl)morpholine;
2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N- dimethy lamino) methyl- 1,2, 3-triazol-4-yl)methyl- 3- (S) -p henylmorp holine ;
2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N- dimethylamino)methyl-l,2,3-triazol-4-yl)methyl-3-(S)-(4- fluorophenyl) morpholine;
2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(3-(4-monophosphoryl-5-oxo-lH-l,2,4-triazolo)methyl)morpholine;
2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(3-(l-monophosphoryl-5-oxo-lH-l, 2, 4-triazolo)methyl)morp holine; 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(3-(2-monophosphoryl-5-oxo-lH-l,2,4-triazolo)methyl)morp holine; 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)- 4-(3-(5-oxyphosphoryl-lH-l, 2, 4-triazolo)methyl)morp holine; 2-(S)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)- 4-(3-(l-monophosphoryl-5-oxo-4H-l, 2, 4-triazolo)methyl)morp holine; 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-N,N- dimethylaminobut-2-yn-yl)-3-(S)-(4-fluorophenyl)morphohne; (3S,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-l-oxa- 7-aza-spiro[4.5]decane;
(3R,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-l-oxa- 7-aza-spiro[4.5]decane;
(±)-(2J?372,2S3S N-{[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]methyl}-2- phenylpiperidin-3-amine; or a pharmaceutically acceptable salt thereof.
12. A use according to anyone of claims 1 to 4, or a composition according to claim 5 or a method according to anyone of claims 6 to 9 wherein the severe anxiety disorder is selected from panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, social phobias or obsessive-compulsive disorders.
13. A use according to anyone of claims 1 to 4, or a composition according to claim 5 or a method according to anyone of claims 6 to 9 wherein the severe anxiety disorder is selected from anxiety disorders induced by alcohol, amphetamines, caffeine, cannabis, cocaine, hallucinogens, inhalants, phencyclidine, sedatives, hypnotics, anxiolytics and other substances, and adjustment disorders with anxiety.
PCT/EP1997/006683 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating severe anxiety disorders WO1998024439A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP97953721A EP0942734A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating severe anxiety disorders
JP52517098A JP2001504848A (en) 1996-12-02 1997-11-25 Use of an NK-1 receptor antagonist for the treatment of severe anxiety disorder
AU57527/98A AU729708B2 (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonists for treating severe anxiety disorders
CA002273785A CA2273785A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating severe anxiety disorders

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB9625051.9 1996-12-02
GB9625051A GB9625051D0 (en) 1996-12-02 1996-12-02 Therapeutic agents
GB9701459A GB9701459D0 (en) 1997-01-24 1997-01-24 Therapeutic agents
GB9701459.1 1997-01-24
GB9713715A GB9713715D0 (en) 1997-06-27 1997-06-27 Therapeutic agents
GBGB9716471.9A GB9716471D0 (en) 1997-08-04 1997-08-04 Therapeutic agents
GB9716471.9 1997-08-04
GBGB9721220.3A GB9721220D0 (en) 1997-10-07 1997-10-07 Therapeutic use
GB9721220.3 1997-10-07
GB9713715.2 1997-10-07

Publications (1)

Publication Number Publication Date
WO1998024439A1 true WO1998024439A1 (en) 1998-06-11

Family

ID=27517384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/006683 WO1998024439A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating severe anxiety disorders

Country Status (5)

Country Link
EP (1) EP0942734A1 (en)
JP (1) JP2001504848A (en)
AU (1) AU729708B2 (en)
CA (1) CA2273785A1 (en)
WO (1) WO1998024439A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064006A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist for treating psychiatric disorders
WO1999064010A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist for treating psychiatric disorders
WO2000007542A2 (en) * 1998-08-07 2000-02-17 Laboratorios Del Dr. Esteve, S.A. Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p
WO2001024791A1 (en) * 1999-10-07 2001-04-12 Warner-Lambert Company Use of synergistic combinations of a nk1 receptor antagonist and a gaba analog in psychiatric disorders
WO2008090117A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014084A2 (en) * 1992-01-21 1993-07-22 Glaxo Group Limited Piperidine derivatives
EP0577394A1 (en) * 1992-06-29 1994-01-05 Merck & Co. Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1995008549A1 (en) * 1993-09-22 1995-03-30 Glaxo Group Limited 3-(5-tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins
WO1995018124A1 (en) * 1993-12-29 1995-07-06 Merck Sharp & Dohme Limited Substituted morpholine derivatives and their use as therapeutic agents
WO1996005181A1 (en) * 1994-08-15 1996-02-22 Merck Sharp & Dohme Limited Morpholine derivatives and their use as therapeutic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1136859A (en) * 1993-10-04 1996-11-27 日用电池有限公司 Process for ultrasonic sealing an anode cap into a gasket for electrochemical cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014084A2 (en) * 1992-01-21 1993-07-22 Glaxo Group Limited Piperidine derivatives
EP0577394A1 (en) * 1992-06-29 1994-01-05 Merck & Co. Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1995008549A1 (en) * 1993-09-22 1995-03-30 Glaxo Group Limited 3-(5-tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins
WO1995018124A1 (en) * 1993-12-29 1995-07-06 Merck Sharp & Dohme Limited Substituted morpholine derivatives and their use as therapeutic agents
WO1996005181A1 (en) * 1994-08-15 1996-02-22 Merck Sharp & Dohme Limited Morpholine derivatives and their use as therapeutic agents

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064006A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist for treating psychiatric disorders
WO1999064010A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist for treating psychiatric disorders
WO2000007542A2 (en) * 1998-08-07 2000-02-17 Laboratorios Del Dr. Esteve, S.A. Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p
WO2000007542A3 (en) * 1998-08-07 2000-05-11 Esteve Labor Dr Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p
ES2150378A1 (en) * 1998-08-07 2000-11-16 Esteve Labor Dr Utilization of aryl(or heteroaryl)azolylcarbinol derivatives for the treatment of troubles mediated by an excess of substance p
US6518295B1 (en) 1998-08-07 2003-02-11 Laboratorios Del Dr. Esteve, S.A. Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P
WO2001024791A1 (en) * 1999-10-07 2001-04-12 Warner-Lambert Company Use of synergistic combinations of a nk1 receptor antagonist and a gaba analog in psychiatric disorders
WO2008090117A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1

Also Published As

Publication number Publication date
EP0942734A1 (en) 1999-09-22
JP2001504848A (en) 2001-04-10
AU5752798A (en) 1998-06-29
CA2273785A1 (en) 1998-06-11
AU729708B2 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
AU731349B2 (en) Use of NK-1 receptor antagonists for treating sexual dysfunctions
AU731672B2 (en) Use of NK-1 receptor antagonists for treating bipolar disorders
EP0942732B1 (en) Use of nk-1 receptor antagonists for treating movement disorders
US5977104A (en) Use of NK-1 receptor antagonists for treating bipolar disorders
EP0941092B1 (en) Use of nk-1 receptor antagonists for treating major depressive disorders
AU731674B2 (en) Use of NK-1 receptor antagonists for treating substance use disorders
WO1998024439A1 (en) Use of nk-1 receptor antagonists for treating severe anxiety disorders
AU732633B2 (en) Use of NK-1 receptor antagonists for treating schizophrenic disorders
EP0941093B1 (en) Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety
EP0942733B1 (en) Use of nk-1 receptor antagonists for treating cognitive disorders
EP0942729A1 (en) Use of nk-1 receptor antagonists for treating stress disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997953721

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 525170

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2273785

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 57527/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1997953721

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 57527/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1997953721

Country of ref document: EP